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1.1 Background 
Spray drying is defined as the conversion of liquid feed into dried particles through spraying 
the atomized feed into a warmer drying gas [1, 2]. The discovery of spray drying goes back to 
the late 19
th
 century. Over the years, this technique has been subjected to lots of modifications 
and improvements. From World War II era until our current time, spray drying gained 
remarkable capabilities and exhibited wide range of applications utilizing the great research 
and technology advancements [2]. 
Spray drying is a single-step technique in which the sprayed product goes through three main 
stages (i.e. atomization, drying and separation). In the first stage, the liquid feed will be 
transformed into fine droplets. Different forms of liquid feeds can be sprayed e.g. solutions, 
emulsions, and suspensions [1, 3]. Atomization devices are available in many types 
e.g. rotatory atomizers, hydraulic nozzles, pneumatic nozzles and ultrasonic nozzles [2]. 
Second stage is drying, wherein the sprayed droplets are subjected to a stream of warmer 
drying gas. Air is typically used as the drying gas. At the end of the drying process, air will be 
filtered and exit the spray dryer without being reused (open-cycle system). However, when 
working with explosive solvents or oxygen sensitive substances, an inert drying gas must be 
used (e.g. nitrogen). In this case, the drying gas will circulate and re-enter the spray dryer 
after passing through special accessory that will extract the solvents from the gas stream 
(closed-cycle system) [3, 4]. 
Sprayed droplets can be mixed with the drying gas using either co-current flow, 
counter-current flow or a combination of both [2, 4]. Each type has its own advantages and 
drawbacks. For instance, in case of using counter-current flow, the sprayed product will be 
more efficiently dried; however, this type is not suitable for thermolabile substances [3]. 
The final stage is when the dried particles separated from the gas stream and collected in the 
product container. This stage takes place inside the separation device e.g. the cyclone [2]. 
The functional principle of the cyclone has been previously described in detail [1]. 
  
CHAPTER I: Introduction 
3 
 
1.2 Spray drying parameters 
One of the spray drying main advantages is the possibility to adjust several process 
parameters (e.g. inlet temperature, drying gas flow rate and feed rate) to produce dried 
particles with desirable physicochemical properties depending on the intended application  
(e.g. morphology, particle size, aerodynamic behavior and residual moisture content) [2-9]. 
 
Table 1 Spray drying process parameters. Reproduced from [4] with permission. 
Parameter 
 
 
Dependence 
Aspirator 
rate 
↑ 
Air 
humidity 
↑ 
Inlet 
temperature 
↑ 
Spray air 
flow 
↑ 
Feed rate 
↑ 
Solvent 
instead 
of water 
Concentration 
↑ 
Outlet 
temperature 
↑↑ 
less heat 
losses 
based on 
total inlet 
of energy 
↑ 
more 
energy 
stored in 
humidity 
↑↑↑ 
direct 
proportion 
↓ 
more cool 
air to be 
heated up 
↓↓ 
more 
solvent to 
be 
evaporated 
↑↑↑ 
less heat of 
energy of 
solvent 
↑↑ 
less water to be 
evaporated 
Particle size - - - 
↓↓↓ 
more 
energy for 
fluid 
dispersion 
(↑) 
more fluid 
to disperse 
(↓) 
less surface 
tension 
↑↑↑ 
more remaining 
product 
Final humidity 
of product 
↑↑ 
lower 
partial 
pressure of 
evaporated 
water 
↑↑ 
higher 
partial 
pressure 
of drying 
air 
↓↓ 
lower relative 
humidity in 
air 
- 
↑↑ 
more water 
leads to 
higher 
particle 
pressure 
↓↓↓ 
no water in 
feed leads to 
very dry 
product 
↓ 
less water 
evaporated, 
lower partial 
pressure 
Yield 
↑↑ 
better 
separation 
rate in 
cyclone 
(↓) 
more 
humidity 
can lead 
to sticking 
product 
(↑) 
eventually 
dryer product 
prevent 
sticking 
- 
(↓↑) 
depends on 
application 
↑↑ 
no 
hygroscopic 
behavior 
leads to 
easier dying 
↑ 
bigger particles 
lead to higher 
separation 
 
  
CHAPTER I: Introduction 
4 
 
An interesting study was previously reported by Paluch et al., wherein they investigated the 
impact of several parameters like feed concentration and solvent composition on the 
physicochemical properties of the spray dried microparticles, especially the morphology. 
Moreover, they introduced a new morphology classification system based on four major 
criteria, namely shape, surface properties, visual morphology and interior of the particles [8]. 
The influence of spray drying process parameters on the powder yield was studied by 
Maury et al. For this reason, they designed a new improved cyclone with enhanced separation 
efficiency. Their findings emphasized the significant role of the cyclone in obtaining higher 
powder yield taking into consideration other important process parameters like inlet 
temperature [10]. 
Recently, several studies reported the optimization of spray drying parameters based on 
advanced statistical designs instead of “trial-and-error” method. This new approach will offer 
systematic development and improvement of spray drying products instead of depending on 
coincidence and luck [11-15]. For instance, Amaro et al. utilized design of experiments 
(DOE) to determine the significance level of several process parameters influencing the 
properties of the produced microparticles. By performing 2
4
 full factorial design (i.e. studying 
four factors at two levels), they aimed to prepare sugar-based respirable formulation with 
improved characteristics [13]. 
 
1.3 Characterizing spray dried particles 
Depending on the intended application, various characterization methods have been utilized to 
investigate the physicochemical properties of spray dried particles. The most common 
characterization methods that are relevant to this work are summarized in Table 2. 
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Table 2 Literature review of the most common characterizations of spray dried particles. 
Properties Methods References 
Particle size Laser diffraction [8, 11-13, 15-25] 
Morphology Scanning electron microscopy [8, 11-13, 15, 17-28] 
Aerodynamic properties 
Glass twin impinger 
Multi-stage liquid impinger 
Andersen cascade impactor 
Next generation impactor 
[12, 17] 
[19, 20] 
[16, 17, 26] 
[13, 21, 22, 25] 
Flowability Carr’s index and Hausner ratio [12, 14, 15, 18, 19, 25] 
Residual moisture content 
Karl Fischer titration 
Thermogravimetric analysis 
[9, 10, 16] 
[11-15, 19, 21] 
Thermal behavior Differential scanning calorimetry 
[8-10, 12, 15, 19, 20, 22, 
25, 28] 
Amorphous/ crystalline X-ray powder diffraction [8, 9, 12, 16, 20, 22, 25, 28] 
Specific surface area Gas adsorption [8, 13, 18, 22, 27] 
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1.4 Applications of spray drying 
Spray drying has a widespread variety of applications ranging from chemical industry 
e.g. ceramic materials, detergents and pigments [1] to food industry e.g. flavors and milk 
products [1, 29] and pharmaceutical applications e.g. improving the bioavailability of drugs 
with poor aqueous solubility and preparing microparticles with controlled release 
properties [30, 31]. In the following subchapters, it will be focused on the applications of 
spray drying dealing with pulmonary drug delivery and nano spray drying. 
 
1.4.1 Pulmonary applications 
In the field of drug delivery, spray drying has been utilized to prepare drug carriers capable of 
delivering various active ingredients to their site of action via several routes of 
administration [3]. The pulmonary route has gained increasing attention because of the 
numerous advantages it offers e.g. being non-invasive route, large surface area (~ 100 m
2
), 
rapid onset of action, and lower concentrations of drug-metabolizing enzymes [32-34]. 
Therefore, pulmonary drug delivery has been used for the treatment of local diseases like 
asthma, chronic obstructive pulmonary disease, and cystic fibrosis as well as systemic 
delivery of many therapeutics [35, 36]. However, in order to achieve successful therapy, 
formulations intended for pulmonary applications must fulfil certain requirements and 
overcome the biological barriers of the lung e.g. mucociliary clearance, mucus penetration, 
macrophage uptake and interaction with pulmonary surfactant [33, 37, 38]. 
In this regard, spray drying has the advantage over other drying techniques in terms of several 
adjustable process parameters capable of producing dried particles with appropriate 
physicochemical properties suitable for pulmonary drug delivery [39, 40]. Moreover, 
parameters related to feed solution (e.g. solvent type and excipients) have been extensively 
investigated to produce particles with improved properties e.g. better aerosolization and 
controlled drug release [17, 21, 26, 40]. Amino acids, especially L-leucine, have been 
commonly used to enhance the dispersibility of inhalable dry powders [19, 41-43]. 
All of these reasons make spray drying such an efficient technique for the preparation of dry 
powders intended for pulmonary delivery of various therapeutic agents e.g. antibiotics [20], 
proteins [44], peptides [45], hormones [46] and nucleic acids [47]. 
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1.4.2 Nano-in-Microparticles (NiMps) 
1.4.2.1 Preparation of NiMps 
Day after day, inhalable nanoscale drug carriers have been showing promising potentials in 
the field of pulmonary drug delivery [48, 49]. Among these nanocarriers are, for example, 
liposomes, solid lipid nanoparticles and polymeric nanoparticles [49-51]. Various strategies 
have been developed to transform nanocarriers into inhalable formulations that can be 
administered using dry powder inhalers, metered-dose inhalers, or nebulizers [52-54]. 
In the last decade, Nano-in-Microparticles (NiMps) emerged as an interesting drug carrier 
with superior aerodynamic properties and higher deposition in the lungs. NiMps are 
microparticles consisting of two main components: nanoparticles and a matrix excipient that 
will serve as a wall material to embed the nanoparticles and stabilize them during the 
atomization process used to produce a more stable dry powder form [55, 56]. 
Although spray drying is the most common preparation method of NiMps [55, 57], other 
atomization techniques e.g. spray freeze drying [54, 58] and supercritical assisted 
atomization [59] were also reported. Furthermore, ultrasonic atomization and electrospraying 
are interesting approaches that can also be employed [55]. 
The first component of NiMps (i.e. nanoparticles) can be produced via various methods e.g. 
solvent evaporation technique [60], modified solvent displacement technique [61], ionotropic 
gelation [62] and high pressure homogenization [63]. 
Biocompatible polymeric nanoparticles have gained increasing interest in this field [54, 57, 
59]. For instance, PLGA-based NiMps have been extensively utilized to encapsulate 
numerous drugs intended for pulmonary applications e.g. rifampicin [64], curcumin [65], 
sildenafil [60], clarithromycin [66], dexamethasone [67] and siRNA [68]. 
Grenha et al. developed NiMps by spray drying chitosan nanoparticles with lactose or 
mannitol as matrix excipients and different nanoparticles:matrix mass ratios were tested. 
Furthermore, the potential of NiMps for pulmonary delivery of peptides and proteins was 
investigated using insulin as a model therapeutic protein [62, 69, 70]. 
Due to it is critical role in stabilizing the nanoparticles, choosing the second component of 
NiMps (i.e. matrix excipient) is one of the most important parameters in preparing NiMps. 
Physicochemical properties of the matrix (e.g. crystallinity and water solubility) and 
nanoparticles:matrix mass ratio will significantly influence the morphology, redispersibility 
and aerodynamic properties of NiMps [56, 61, 71, 72]. 
CHAPTER I: Introduction 
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The most frequently used matrix excipients are sugars (e.g. mannitol [68, 72-74], 
trehalose [71] and lactose [75]), biocompatible polymers (e.g. chitosan [63, 65]), and amino 
acids (e.g. arginine and L-leucine [64]). 
Despite the several advantages of using matrix excipient, previous study reported the 
preparation of excipient-free PLGA-based NiMps [60]. Using the Nano Spray Dryer B-90, 
Beck-Broichsitter et al. transformed PLGA nanoparticles into composite particles without 
adding any additional excipient to the formulation. Interestingly, the produced particles 
exhibited aerodynamic behavior suitable for pulmonary applications. Moreover, the prepared 
NiMps have a good redispersibility in aqueous media and were able to disintegrate into the 
original nanoparticles without significant increase in mean particle size. 
It is worthwhile to mention that NiMps have been recently used for other applications beside 
pulmonary drug delivery. Elbaz et al. prepared NiMps intended for the oral delivery of 
propolis extract loaded nanoparticles against liver and colon cancer [76]. Different types of 
propolis loaded nanoparticles were dispersed in chitosan solution and spray dried using Nano 
Spray Dryer B-90. 
 
1.4.2.2 Characterization of NiMps 
Redispersibility 
Once NiMps are deposited in the lung, they should rapidly disintegrate and release the 
original nanoparticles intact and fully functional [56, 72]. Therefore, NiMps should exhibit 
good redispersibility in lung lining fluid to achieve an effective therapy and evade 
macrophage clearance [61, 77]. 
As mentioned previously, type of matrix excipient and nanoparticles:matrix mass ratio have 
significant impact on the redispersibility of NiMps. Additionally, Wang et al. discussed 
further important parameters [56]. Several types of nanoparticles and excipients with different 
properties were investigated. They found that the hydrophilicity of the nanoparticles is 
directly proportional to the amount of excipient required to stabilize them. They also reported 
that PLGA-based NiMps prepared with amorphous excipients (e.g. trehalose) exhibited better 
redispersibility in comparison to those prepared with crystalline excipients (e.g. mannitol). 
In most studies, NiMps have been redispersed in aqueous media (e.g. pure water or buffer) 
sometimes with aid of mechanical forces e.g. shaking or ultrasound. The quality of the 
redispersed nanoparticles was determined mainly based on particle size and morphology 
measurements. Usually, no significant change in the physiochemical properties of the 
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redispersed nanoparticles has been observed. Few studies reported significant increase in the 
particle size after spray drying. This change; however, was still considered to be in the 
acceptable ranges [60, 61, 64, 69, 70, 73, 77, 78]. 
However, most of redispersibility experiments have been performed under conditions that do 
not take the realistic in vivo environment into consideration [71, 72]. To address this issue, 
Ruge et al. investigated the disintegration behavior of NiMps upon deposition onto model 
mucus layer under different conditions (i.e. static conditions or agitation). Using fluorescence 
microscopy, it was found that even when the matrix excipient (i.e. trehalose) was completely 
dissolved, without sufficient shear forces the nanoparticles did not disintegrate from NiMps 
and remained in their nanoaggregate form [71]. In another study, Torge et al. evaluated the 
redispersibility of PLGA-based NiMps by measuring the particle size of the redispersed 
nanoparticles in a simulated lung fluid using dynamic light scattering (DLS). Furthermore, 
they performed surface roughness measurements to study the disintegration behavior of 
NiMps on agarose gel pads thereby imitating lung conditions in terms of relative humidity 
and temperature. The rate of disintegration and redispersible fraction were directly 
proportional to the matrix excipient content (i.e. mannitol). This latter played a significant 
role in stabilizing the nanoparticles and preserving their original properties [72]. 
 
Morphology 
Morphology and surface structure of NiMps are also important properties that have been 
investigated to develop more efficient NiMps and offer better understanding of the process 
parameters and their significance. Scanning electron microscopy (SEM) is the most used 
method to study the morphology of NiMps and observe their composite structure (Figure 1). 
Usually, DLS measurements are used to support SEM findings and evaluate the intactness of 
redispersed nanoparticles by observing significant variations in the particle size before and 
after spray drying [60, 61, 71-73, 79-81]. 
Fluorescence microscopy has been employed to visualize the detailed structure of NiMps and 
the distribution of the nanoparticles within the matrix excipient. This is usually performed by 
labelling the nanoparticles and the matrix excipient with two different fluorophores [62, 67, 
72, 82]. 
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Figure 1 SEM micrographs showing the influence of nanoparticles:matrix mass ratio on the 
morphology of NiMps which were prepared by spray drying polystyrene nanoparticles with 
different amounts of trehalose (A: 0%, B: 0.1%, C: 0.2% and D: 0.4%). Scale bars represent 
1 µm. Reproduced from [71] with permission. 
 
Recently, correlative light and electron microscopy (CLEM) was developed as a new 
characterization method that utilizes the benefits of two well-known technologies i.e. SEM 
and fluorescence microscopy. Thus, offering a detailed morphology and colorful images of 
the examined sample [83, 84]. However, this method has not been exploited yet as a 
characterization method to study the morphology of NiMps. Later in this work, this method 
will be explained in detail pointing out its main advantages. 
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1.4.3 Nano spray drying 
Just a few years ago, nano spray drying technique has emerged. Equipped with several 
cutting-edge technologies, the Nano Spray Dryer B-90 (Figure 2) was introduced by BÜCHI 
Labortechnik AG paving the way for numerous innovative applications, especially in the field 
of pulmonary drug delivery and preparation of drug nanocrystals [3, 60, 72, 85-92]. 
This spray dryer is a laboratory-scale device that has the ability to produce particles in the 
submicron range due to its unique spray head technology which has a spray mesh that can 
vibrate at ultrasonic frequency (60 kHz) to generate ultra-fine droplets [85, 88, 93]. 
These droplets will be dried into solid particles in the drying chamber by a laminar gas flow. 
Subsequently, the dried particles will get a negative charge and be deflected towards the 
electrostatic particle collector due to an electric field generated between the star-shaped 
electrode and the particle collector [86, 88]. Detailed description of the functional principle of 
the Nano Spray Dryer B-90 is comprehensively described in previous studies [85, 86, 88, 90]. 
 
 
Figure 2 The Nano Spray Dryer B-90 with an illustration showing the functional principle of 
the spray mesh. Reproduced from [89] with permission. 
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Figure 3 Diagram showing the difference in the functional principle between the Nano Spray 
Dryer B-90 (left) and the Mini Spray Dryer B-290 (right) from BÜCHI Labortechnik AG. 
The main process parameters are also presented. Reproduced from [87] with permission. 
 
Table 3 Comparison between the Nano Spray Dryer B-90 and the Mini Spray Dryer B-290 
from BÜCHI Labortechnik AG. Reproduced from [94] with permission. 
 Nano Spray Dryer B-90 Mini Spray Dryer B-290 
Main benefit for small quantities, finest particles, 
highest yields 
for traditional spray drying, 
established process 
Max. inlet temperature 120 °C 220 °C 
Water evaporation max. 0.2 kg/h 1.0 kg/h, higher for solvents 
Nozzle type piezoelectric driven vibrating mesh two-fluid nozzle 
Particle size 300 nm – 5 μm 2 – 25 μm 
Particle separation electrostatic particle collector cyclone 
Typical yield up to 90% typically around 60% 
Min. sample volume 1 ml 30 ml 
Max. sample viscosity 10 cps (diluted samples) 300 cps (viscous samples 
and juices possible) 
Scale-up limited by spray head and electrical 
particle collector 
possible to scale-up to kg- 
and tons-scale 
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Nano spray drying has several advantages over conventional spray drying in terms of ability 
to produce nanoparticles by generating far smaller droplets with narrower size distribution, 
gentle drying conditions due to laminar flow of the drying gas, smaller sample quantities are 
required, and higher powder yields are achievable [3, 85, 86, 88, 90]. However, there are still 
some limitations associated with nano spray drying that need to be addressed, e.g. upscaling 
difficulties and inability to spray highly viscous solutions [3, 88, 95]. 
Recently, an interesting attempt to expand the capabilities of nano spray drying was reported. 
Beck-Broichsitter et al. introduced a new approach to modify the spray mesh of the 
Nano Spray Dryer B-90 using polymeric coating. They have succeeded to reduce the size of 
the generated droplets which lead to the formation of even smaller dried particles with 
narrower size distribution [96]. 
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1.5 Aims and scope 
This work was focused on innovative utilizations of spray drying in two interesting fields. 
 
The first field was pulmonary drug delivery, where the aim was to develop a photosensitizer 
loaded formulation in the form of a dry powder for inhalation, which together with 
bronchoscopic photodynamic therapy would offer an effective treatment against lung cancer. 
The means to accomplish this objective laid within the answers of the following questions: 
1. Which photosensitizer should be chosen? Could nanoencapsulation enhance its phototoxic 
effect against tumor cells? Which nanoparticle preparation method would be suitable? 
2. What would be the physicochemical properties of the produced nanoparticles? What about 
their in vitro phototoxicity? 
3. Would it be feasible to transform these nanoparticles into an inhalable formulation via 
spray drying? Which matrix excipient would be appropriate to produce Nano-in-
Microparticles with suitable aerodynamic properties? 
4. Which characterization method would give a better understanding of the structure of the 
Nano-in-Microparticles? 
5. Would the Nano-in-Microparticles be able to disintegrate into the original nanoparticles 
upon redispersion? To what extent would they be compatible with pulmonary surfactant? 
 
The second field was coating and surface modification of medical implants, where the key 
objective was to introduce nano spray drying as a novel coating technique with promising 
potentials. To achieve this goal, the following questions needed to be answered: 
1. Would it be possible to manage particle production and implant coating in a single step? 
2. Which process parameters will have a major influence on particle size distribution and 
surface coverage? Should these parameters first be optimized on a model material? 
3. How to implement this coating technique in the surface modification of actual medical 
implants like dental implants and coronary stents? Would it generate the same results? 
4. Could this method be employed in producing biocompatible nanocoatings with potent 
antibacterial activity? Which characterizations should be carried out to investigate their 
full potentials and study their characteristics? 
 15 
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2.1 Materials 
2.1.1 List of materials and devices 
Materials Source 
12-well plates, 
Nunclon™ Delta 
Thermo Fischer Scientific GmbH 
Dreieich, Germany 
24-well plates, 
Standard, F 
Sarstedt AG & Co. KG 
Nümbrecht, Germany 
5 ml glass vials 
Schott AG 
Müllheim, Germany 
5 ml screw cap tubes 
Sarstedt AG & Co. KG 
Nümbrecht, Germany 
96-well plates, 
Nunclon™ Delta 
Thermo Fischer Scientific GmbH 
Dreieich, Germany 
96-well plates, 
UV-Star
®
, half area 
Greiner Bio One International GmbH 
Frickenhausen, Germany 
A549 cells 
ATCC
®
 
Manassas, USA 
Alveofact
®
 
Lyomark Pharma GmbH 
Oberhaching, Germany 
Antibiotic/antimycotic solution 
Capricorn Scientific GmbH 
Ebsdorfergrund, Germany 
BD
TM
 Mueller Hinton II agar plates  
BD GmbH 
Heidelberg, Germany 
Centrifuge, 
5418 
Eppendorf AG 
Hamburg, Germany 
Clear disposable folded capillary cell, 
DTS1060 
Malvern Panalytical GmbH 
Herrenberg, Germany 
CLSM, 
LSM 700 
Carl Zeiss Microscopy GmbH 
Jena, Germany 
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CLSM, 
LSM 710 NLO 
Carl Zeiss Microscopy GmbH 
Jena, Germany 
CO2 incubator, 
In-VitroCell ES NU-5841E 
NuAire, Inc. 
Plymouth, MN, USA 
Coagulation analyzer, 
Coatron
®
 M1 
Teco Gmbh 
Neufahrn, Germany 
Conductive adhesive carbon tabs 
Agar Scientific Ltd 
Stansted, United Kingdom 
Coronary stent, 
Camouflage
®
 coronary stent system 
eucatech AG 
Rheinfelden, Germany 
Coumarin 6, 
laser grade, 98%  
Acros Organics 
Geel, Belgium 
Cover slips, 
Ø 15 mm 
Gerhard Menzel B.V. & Co. KG 
Braunschweig, Germany 
Critical flow controller, 
TPK 
Copley Scientific AG 
Therwil, Switzerland 
Curcumin, 
≥ 80% 
Sigma-Aldrich Chemie GmbH 
Taufkirchen, Germany 
DAPI 
Sigma-Aldrich Chemie GmbH 
Taufkirchen, Germany 
Dental implants, 
AR Fixture, R-Type, Regular 
Biotem Co., Ltd 
South Korea 
Digital image acquisition system 
DISS 5 
Point Electronic GmbH 
Halle, Germany 
di-Sodium hydrogen phosphate dehydrate, 
≥ 99% 
Merck KGaA 
Darmstadt, Germany 
D-Mannitol, 
≥ 98% 
Sigma-Aldrich Chemie GmbH 
Taufkirchen, Germany 
DMEM 
Capricorn Scientific GmbH 
Ebsdorfergrund, Germany 
Dry powder inhaler, 
Handihaler
®
 
Boehringer Ingelheim 
Ingelheim, Germany 
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Escherichia coli DH5α, 
DSM 6897 
DSMZ 
Braunschweig, Germany 
Fetal bovine serum 
Sigma-Aldrich Chemie GmbH 
Taufkirchen, Germany 
Film balance, 
teflon trough 
Riegler & Kirstein GmbH 
Potsdam, Germany 
Flow meter, 
DFM 2000 
Copley Scientific AG 
Therwil, Switzerland 
Fluorescence light source, 
U-HGLGPS 
Olympus Deutschland GmbH 
Hamburg, Germany 
FluorSave™ reagent 
Calbiochem Corp 
San Diego, California, USA 
GIBCO
®
 Trypan blue stain 0.4% 
Life Technologies, Inc. 
Grand Island, New York, USA 
High capacity pump, 
HCP5 
Copley Scientific AG 
Therwil, Switzerland 
Inert Loop B-295 
BÜCHI Labortechnik AG 
Flawil, Switzerland 
Inverted microscope, 
CKX53 
Olympus Deutschland GmbH 
Hamburg, Germany 
L929 cells 
ATCC
®
 
Manassas, USA 
Low power LED irradiating device, 
prototype 
Lumundus GmbH 
Eisenach, Germany 
Magnetic stirrer, 
IKA RT 15 
IKA Werke GmbH & Co. KG 
Staufen, Germany 
MHB 
Sigma-Aldrich Chemie GmbH 
Taufkirchen, Germany 
Microplate reader, 
FLUOstar
®
 OPTIMA 
BMG Labtech 
Ortenberg, Germany 
Microplate spectrophotometer, 
Multiskan
™
 GO 
Thermo Fisher Scientific 
Waltham, Massachusetts, USA 
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Mini Spray Dryer B-290 
BÜCHI Labortechnik AG 
Flawil, Switzerland 
MTT dye 
Sigma-Aldrich Chemie GmbH 
Taufkirchen, Germany 
Nano Spray Dryer B-90 
BÜCHI Labortechnik AG 
Flawil, Switzerland 
NGI 
Copley Scientific AG 
Therwil, Switzerland 
Norfloxacin, 
≥ 98% 
Sigma-Aldrich Chemie GmbH 
Taufkirchen, Germany 
Orbital shaker, 
Compact Shaker KS 15 A 
Edmund Bühler GmbH 
Bodelshausen, Germany 
Orbital shaker, 
KS4000 IC 
IKA Werke GmbH & Co. KG 
Staufen, Germany 
PLGA, 
Resomer
®
 RG 503 H 
Evonik Nutrition & Care GmbH 
Essen, Germany 
Polyethylene capsules, 
size 3 
RPC Formatec 
Mellrichstadt, Germany 
Potassium chloride, 
≥ 99.5% 
Merck KGaA 
Darmstadt, Germany 
Potassium dihydrogen phosphate, 
≥ 99.5% 
Merck KGaA 
Darmstadt, Germany 
PVA, 
Mowiol
®
 4-88 
Kuraray Europe GmbH 
Frankfurt, Germany 
Rhodamine B, 
for fluorescence 
Sigma-Aldrich Chemie GmbH 
Taufkirchen, Germany 
Rotary-Pumped Sputter Coater, 
Q150R ES 
Quorum Technologies Ltd 
East Grinstead, UK 
Roti
®
-Histofix 4%, 
phosphate-buffered formaldehyde solution 4% 
Carl Roth GmbH + Co. KG 
Karlsruhe, Germany 
SEM, 
EVO HD15 
Carl Zeiss Microscopy GmbH 
Jena, Germany 
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SEM, 
Hitachi S-510 
Hitachi High-Technologies Europe GmbH 
Krefeld, Germany 
Sodium acetate, 
≥ 98.5% 
Carl Roth GmbH + Co. KG 
Karlsruhe, Germany 
Sodium chloride, 
> 99.8% 
Carl Roth GmbH + Co. KG 
Karlsruhe, Germany 
Sputter coater, 
Edwards S150 
Edwards Vacuum 
Crawley, UK 
Sputter coater, 
Gatan Alto 2500  
Gatan GmbH 
München, Germany 
Stereomicroscope, 
Stemi 2000-C 
Carl Zeiss Microscopy GmbH 
Jena, Germany 
Superspeed Centrifuge, 
Sorvall RC6 Plus™ 
Thermo Fisher Scientific 
Waltham, Massachusetts, USA 
TEClot aPTT-S Kit 
Teco GmbH 
Neufahrn, Germany 
Titanium foil, 
0.25 mm thick, annealed 
Alfa Aesar 
Karlsruhe, Germany 
Trypsin-EDTA, 
(0.5%) in DPBS (10x) 
Capricorn Scientific GmbH 
Ebsdorfergrund, Germany 
Ultra-pure chitosan chloride, 
Protasan™ UP CL 113  
FMC BioPolymer AS 
Sandvika, Norway 
Ultrasound bath, 
Elmasonic P 
Elma Schmidbauer GmbH 
Singen, Germany 
Zetasizer Nano ZS 
Malvern Panalytical GmbH 
Herrenberg, Germany 
 
2.1.2 Solvents 
All solvents were of analytical or HPLC grade and were used as received. Ultrapure water 
from PURELAB® flex 4 equipped with a Point-of-Use biofilter (ELGA LabWater, UK) was 
used for all experiments. 
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2.1.3 Cell culture 
All cell lines were purchased from American Type Culture Collection (ATCC
®
). The cells 
were cultivated in monolayers and passaged upon reaching 80% confluency. 
2.1.3.1 Human lung epithelial carcinoma cells (A549) 
A549 cells were maintained at 37 ºC and 5 % CO2 under humid conditions and were cultured 
in DMEM medium supplemented with 10% fetal bovine serum. 
2.1.3.2 Mouse fibroblasts (L929) 
L929 cells were maintained at 37 ºC and 8.5% CO2 under humid conditions and were cultured 
in DMEM medium supplemented with 10% fetal bovine serum and 10 µl/ml 
antibiotic/antimycotic solution (amphotericin B, penicillin and streptomycin). 
2.1.4 Bacterial strains 
Escherichia coli DH5α (DSM 6897, DSMZ) were cultured in MHB and stored at -80 °C. 
One day prior to the bacterial experiments, the bacteria were thawed and then incubated 
overnight at 37°C under gentle shaking (100 rpm) using an orbital shaker (Compact Shaker 
KS 15 A, Edmund Bühler GmbH). 
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2.2 Methods 
2.2.1 Nano-in-Microparticles for pulmonary applications 
2.2.1.1 Preparation of nanoparticles 
Curcumin loaded PLGA nanoparticles (PLGA.CUR.NPs) were prepared according to the 
nanoprecipitation method with slight modifications [97]. Briefly, 200 mg PLGA and 5 mg 
curcumin were dissolved in 10 ml acetone (organic phase). A beaker filled with a 40 ml of 
0.5% PVA solution (aqueous phase) was placed on a magnetic stirrer (IKA RT 15, 
IKA Werke) at medium stirring speed (400 rpm). The organic phase was injected into the 
aqueous phase and the mixture was left stirring under light-protected conditions until 
complete evaporation of acetone. Afterwards, the final volume was adjusted to 50 ml using 
water and the nanoparticles were stored at 4 °C until further characterization. Unloaded 
nanoparticles (PLGA.NPs) were also prepared following the same procedure except that the 
organic phase consisted only of PLGA. Scheme of nanoparticles preparation is illustrated in 
Figure 4. To determine the amount of free curcumin, freshly prepared nanoparticles were 
centrifuged at 2,000 g for 2 min (Centrifuge 5418, Eppendorf AG). The supernatant was 
carefully collected and the resulting pellet which contained the large free curcumin crystals 
was completely dissolved in ethanol. The amount of free curcumin was then quantified using 
a microplate spectrophotometer (Multiskan™ GO, Thermo Scientific) by measuring the 
absorbance at λ = 420 nm. 
Encapsulation efficiency (EE%) was calculated according to the following equation: 
 
EE% =  
Total amount of curcumin − Amount of free curcumin (mg)
Total amount of curcumin (mg)
∗ 100 
 
 
Figure 4 Scheme of preparation of curcumin loaded PLGA nanoparticles according to the 
nanoprecipitation method. 
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2.2.1.2 Particle size distribution and ζ-potential 
Dynamic light scattering (DLS) and laser Doppler velocimetry (LDV) were performed using 
Zetasizer Nano ZS (Malvern Panalytical GmbH) to determine the particle size and ζ-potential 
respectively. The samples were diluted 1:100 with phosphate-buffered saline (PBS, pH 7.4) 
and then placed in a clear disposable folded capillary cell (DTS1060, Malvern 
Panalytical GmbH). Prior to measurements, temperature of the samples was equilibrated to 
25 °C. This instrument is equipped with Non-Invasive BackScatter (NIBS) technology that 
uses a detection angle of 173°. Measurement duration and number of sub-runs were 
automatically adjusted by the instrument [98]. 
2.2.1.3 Scanning electron microscopy 
The morphology and particle size of the nanoparticles were investigated using scanning 
electron microscopy (SEM). The sample was pipetted onto a silica wafer and left to dry. 
Afterwards, the sample was sputtered with gold at a current of 20 mA for 50 s (Q150R ES, 
Quorum Technologies Ltd). The sample holder was then placed in the SEM (EVO HD15, 
Carl Zeiss Microscopy GmbH) and images were taken with an acceleration voltage of 5 kV 
and a secondary electron detector. Particle size analysis of the SEM micrographs was 
performed by measuring the diameter of a representative number of particles (n = 250) using 
ImageJ software (version 1.47, National Institutes of Health). 
2.2.1.4 Activated partial thromboplastin time (aPTT) test 
aPTT test was performed to determine the effect of the nanoparticles on blood coagulation. 
Fresh blood was drawn into citrate tubes followed by centrifugation at 1500 g for 10 min to 
separate the plasma fraction. The aPTT test was performed in a Coatron M1 coagulation 
analyzer (Teco Gmbh) using the TEClot aPTT-S Kit as per the manufacturer’s protocol with 
slight modifications [99]. Briefly, 25 μl of plasma was mixed with 25 μl of either PLGA.NPs 
or PLGA.CUR.NPs. 25 μl of aPTT reagent was added to the mixture to activate coagulation 
factors followed by the addition of prewarmed 0.025 M calcium chloride. Coagulation was 
confirmed spectrophotometrically, and the time was recorded in seconds. 
2.2.1.5 Hemolysis assay 
To investigate the hemolytic potential of the nanoparticles, human erythrocytes were isolated 
from fresh blood as described previously [100]. Briefly, fresh blood was drawn into tubes 
containing EDTA followed by centrifugation of the whole blood. The obtained red blood cell 
pellet was washed thrice with PBS (pH 7.4) and diluted (1:50) with PBS. The erythrocytes 
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were incubated together with the nanoparticles for 1 h at 37 °C in V-bottom microtiter plates 
in an orbital shaker (KS4000 IC, IKA Werke GmbH & Co. KG). The plates were then 
centrifuged, and the absorbance of the collected supernatant was determined at λ = 540 nm 
using a plate reader (FLUOstar® OPTIMA, BMG Labtech). PBS (pH 7.4) and 
1% Triton X-100® were used as controls and the absorbance values of Triton X-100® were 
considered as 100% hemolysis. 
2.2.1.6 In vitro cytotoxicity and irradiation experiments 
A prototype low power LED device (Lumundus GmbH) was used as light source to irradiate 
the cells. Detailed device description was previously mentioned elsewhere [101]. A549 cells 
were seeded onto 96-well plates (Nunclon™ Delta, Thermo Fischer Scientific GmbH) at a 
seeding density of 10,000 cells/0.35 cm
2
 (per well). After 24 h, the cells were incubated for 
4 h with several concentrations of PLGA.CUR.NPs (i.e. 1.56 - 100 µM of curcumin) and 
equivalent volumes of PLGA.NPs. Subsequently, the samples were removed, and fresh 
medium was added. The cells were irradiated at λ = 457 nm with different radiation fluence 
levels (i.e. 33.03 and 66.06 J/cm
2
) and were incubated overnight for 24 h. Unirradiated 
microtiter plate (dark) and untreated cells (blank) were used as controls. After the incubation 
time, the medium was removed, and the cells were incubated for 4 h with fresh medium 
containing dissolved MTT (1:10, 0.2 mg/ml). The remaining medium was then aspirated and 
200 µl of DMSO were added to each well to dissolve the resulting formazan crystals. 
The absorbance was measured at λ = 570 nm (FLUOstar® OPTIMA). Viability of blank cells 
was considered as 100%. 
2.2.1.7 Visualization with confocal laser scanning microscope 
For the visualization experiments, 90,000 cells/3.5 cm
2
 (per well) were seeded onto 12-well 
plates (Nunclon™ Delta, Thermo Fischer Scientific GmbH) containing cover slips 
(Ø 15 mm). After 24 h, the cells were incubated with PLGA.CUR.NPs containing 100 µM 
curcumin or an equivalent volume of PLGA.NPs. After 4 h, the supernatant was removed and 
replaced with fresh medium and the plates were irradiated at a radiation fluence of 
33.03 J/cm
2
. Unirradiated cells (dark) were used as a control. The cells were then washed with 
PBS containing Ca
2+
 and Mg
2+
 (pH 7.4) and fixed with 4% formaldehyde solution for 20 min. 
For counterstaining the cell nucleus, the cells were incubated with DAPI (0.1 µg/ml) for 
20 min. Finally, the cells were washed with PBS (pH 7.4) and the cover slips were mounted 
onto glass slides and sealed using FluorSave™ (Calbiochem Corp, La Jolla, USA). 
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Subsequently, the cellular uptake of the nanoparticles and their photoresponse were visualized 
using confocal laser scanning microscope (CLSM) (Zeiss Axio Observer Z1 equipped with an 
LSM 700 confocal unit, Carl Zeiss Microscopy GmbH). All micrographs were recorded with 
a similar detector gain and pinhole size. 
2.2.1.8 Preparation of Nano-in-Microparticles  
The nanoparticles were centrifuged at 13,000 rpm (20,064 g) for 60 min at 4 °C (Sorvall RC6 
Plus™ Superspeed Centrifuge, Rotor F21-8x50y, Thermo Scientific). The supernatant was 
carefully collected, and the pellet was redispersed in a solution of mannitol (matrix substance) 
and rhodamine B (0.1 wt% of mannitol) with a mass ratio of 30:70 (nanoparticles:matrix) and 
the solid concentration was adjusted to 1% (w/v) with water. Nano-in-Microparticles (NiMps) 
were prepared by spray drying the mixture of nanoparticles and mannitol using the 
Min Spray Dryer B-290 (BÜCHI Labortechnik AG) equipped with two-fluid nozzle as 
previously described [61]. The process parameters were set as follows: inlet temperature 
65 °C, aspirator 100%, pump rate 7%, spray gas flow 536 l/h, nozzle cleaner 1, outlet 
temperature ≤ 41 °C. The spray dried product was collected with high performance cyclone 
and the yield% was calculated using the following equation: 
 
Yield% =  
Amount of the collected spray dried product (mg)
Total amount of  constituents used for preparation (mg)
∗ 100 
 
2.2.1.9 Redispersibility 
NiMps should be readily dispersible in aqueous media and disintegrate into the original 
nanoparticles. Therefore, a specific amount of the spray dried powder was weighed and 
redispersed in water with a final concentration of 1 mg/ml. The sample was vortexed for 30 s 
and then placed in an ultrasound bath for 60 s at room temperature. Subsequently, particle size 
distribution of the redispersed sample was investigated using DLS [71]. 
2.2.1.10 Correlative light and electron microscopy  
Correlative light and electron microscopy (CLEM) is a microscopy technique, based on the 
combination of electron and light microscopy. The Shuttle & Find setup (Carl Zeiss 
Microscopy GmbH) offers a modular system of standardized hardware and software for a 
straightforward relocation of any region of interest (ROI), both in the CLSM (LSM 710 NLO, 
Carl Zeiss Microscopy GmbH) and SEM (EVO HD15). The general procedure was described 
earlier [84]. Due to the calibration of the Shuttle & Find specimen holder, each image was 
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saved with its coordinates allowing relocating the reference point. No additional manipulation 
of the sample was necessary. The light microscopy was performed first, owing to possible 
interference between the electron beam and the fluorophores [83]. The microparticles were 
placed on a high precision coverslip (22x22 mm, 0.17 mm thickness) and loose particles were 
removed with a stream of air. For the electron microscope, the sample was then sputtered with 
a gold layer of ~30 nm using a current of 20 mA for 100 s (Q150R ES). Images were taken 
with an acceleration voltage of 5 kV and a secondary electron detector. The “Shuttle and 
Find” function in the ZEN 2 (blue edition) software combines both microscope images 
together into one overlaying image. 
2.2.1.11 Aerodynamic properties 
Next generation impactor (NGI) (Copley Scientific AG) was used to determine the 
aerodynamic properties of NiMps. Polyethylene capsule (size 3) was filled with approx. 
20 mg of the spray dried powder. Handihaler® (Boehringer Ingelheim) was used as dry 
powder inhaler. All NGI cups were coated with an anti-bouncing agent (Brij® 35/glycerol). 
Prior to experiment, the air flow rate was adjusted using flow meter (DFM 2000, 
Copley Scientific AG), critical flow controller (TPK, Copley Scientific AG) and high capacity 
pump (HCP5, Copley Scientific AG). To perform the test, one filled capsule was placed in the 
Handihaler® then punctured. The pump was then turned on and the powder was aerosolized 
at a flow rate of 60 l/min for 4 s. Afterwards, water was used to rinse the induction port, 
pre-separator and the cups of the impactor. To calculate mass median aerodynamic diameter 
(MMAD), geometric standard deviation (GSD) and fine particle fraction (FPF), the amount of 
particles in each stages was quantified by measuring the fluorescence (λex = 540 nm, 
λem = 610 nm) using a plate reader (FLUOstar® OPTIMA) [72]. 
2.2.1.12 Langmuir film balance  
Langmuir film balance was utilized as in vitro model to investigate the biophysical properties 
of pulmonary surfactant upon contact with the nanoparticles. Using the naturally-derived 
pulmonary surfactant; Alveofact
®
, alveoli specific surface pressures could be generated. The 
surface pressure (π) is the difference between the surface tension of pure water (γ0) and the 
measured surface tension (γ). 
π = γ0 - γ 
Surface pressure measurements in the film balance (Riegler & Kirstein GmbH; Teflon trough 
100 ml total volume and total area of 171 cm
2
) were performed according to Wilhelmy-
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method [102]. Alveofact® was dissolved in cyclohexane to a final concentration of 1 mg/ml. 
PBS (pH 7.4, filtered through 0.2 μm syringe filter) was used as the subphase (i.e. the aqueous 
medium on which the monolayer will spread). All experiments were performed at 25°C. 
5 min after spreading Alveofact® on the surface, the monolayer was formed. The monolayer 
was compressed, and the total surface area was reduced to generate two different surface 
pressures (i.e. 25 mN/m and 42 mN/m). Afterwards, the monolayer was left to stabilize for 
15 min. PLGA.CUR.NPs were then injected under the monolayer into the subphase. The π-t 
(pressure-time) isotherms were recorded by a control unit (Riegler & Kirstein). 
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2.2.2 Nano spray drying for coating of medical implants 
2.2.2.1 Preliminary experiments 
Nano Spray Dryer B-90 (BÜCHI Labortechnik AG) was used to produce nanoparticles which 
will coat the medical implants. In this study, the electrostatic particle collector was utilized in 
a different approach. The implants were fixed on the electrostatic collector using conductive 
adhesive carbon tabs (Agar Scientific Ltd). Thus, the implant surface will gain the same 
charge of the particle collector since they are made of titanium which is a conductive metal. 
Therefore, the dried particles will deposit also on the implant surface forming a homogenous 
layer of nanoparticles. The scheme of particle production and coating of the implants is 
illustrated in Figure 5. 
To prove the feasibility of this technique, three model substances were tested. The first 
substance chosen was chitosan which is a semi-synthetic polymer obtained from the 
deacetylation of the natural polymer chitin. Chitosan has a variety of biomedical applications, 
e.g. tissue engineering and wound healing [27, 103, 104]. The second model substance was 
PLGA which is a biodegradable and biocompatible synthetic polymer that has been exploited 
in the field of drug delivery and controlled release formulations [105-107]. Finally, curcumin 
was chosen as a model substance for hydrophobic natural compounds. Curcumin has 
antioxidant and anti-inflammatory activities and has proven its efficacy against cancer and 
several chronic diseases [101, 108-110]. 
0.1% solution of each was prepared with the suitable solvent or solvents mixture. For the 
purpose of visual inspection, 1% rhodamine B and 1% coumarin 6 were added to the solutions 
of chitosan and PLGA, respectively. Spray cap of 4.0 µm mesh diameter (45° angular 
position) and tall set-up of the Nano Spray Dryer B-90 were used for all formulations. 
The combination of Nano Spray Dryer B-90 with the Inert Loop B-295 (BÜCHI 
Labortechnik AG) enabled operating the device in closed loop mode which allowed the safe 
use of organic solvents. Oxygen levels were kept below 4%. Spray drying parameters were 
chosen depending on the properties of the sprayed substance taking into consideration 
previous studies [111]. A summary of the experimental parameters is presented in Table 4. 
Preliminary experiments were performed on titanium plates to determine the appropriate 
amount of sprayed sample and the optimal position of the implant inside the particle collector. 
The titanium plates (1.5x1.5 cm) were cut from a titanium foil (0.25 mm thick, annealed, 
99.5% (metals basis); Alfa Aesar). Prior to use, they were thoroughly cleaned using several 
solvents with the aid of ultrasound bath (Elmasonic P, Elma Schmidbauer GmbH). 
CHAPTER II: Materials and methods 
29 
 
Three different positions were chosen to fix the titanium plates on the particle collector (Top, 
Middle and Bottom) with approx. 6 cm distance between each of them. Subsequently, the 
optimized parameters were applied on dental implants (Internal submerged system, 
AR Fixture, R-Type, Regular Ø 4.0 mm, length: 11.5 mm, Biotem Co., Ltd.) which were 
placed approx. 12 cm towards the bottom of the particle collector. 
 
Table 4 Summary of spray drying parameters 
 
 
Figure 5 Illustration of the functional principle of the Nano Spray Dryer B-90 and the coating 
of the implants. 
 Chitosan PLGA Curcumin 
Solvent H2O ACN:H2O (95:5) + 0.005% NaOAc ACE:ETOH (1:1) 
Drying gas Compressed air N2/ CO2 N2/ CO2 
Gas flow [l/min] 100 100 100 
Spray rate [%] 100 50 50 
Inlet temperature [°C] 120 55 75 
Outlet temperature [°C] 40 - 46 28 - 34 35 - 41 
Feed rate [ml/h] 41.98 54.30 26.39 
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2.2.2.2 Visualization 
To confirm the homogenous coating of the dental implants, initial visual inspections of the 
implants before and after spray drying were performed using a stereomicroscope (Zeiss Stemi 
2000-C, Carl Zeiss). Afterwards, CLSM was used to examine the coating uniformity of the 
implants using an Axio Observer Z1 inverted microscope equipped with an LSM700 confocal 
unit (Carl Zeiss). 
2.2.2.3 Scanning electron microscopy 
Morphology and surface structure studies were done using a Hitachi S-510 SEM (Hitachi 
High-Technologies Europe GmbH). The titanium plates and the dental implants were fixed on 
aluminum pin stubs. The samples were sputter-coated with a platinum layer (10 mA for 
2 min) using a Gatan Alto 2500 sputter coater (Gatan GmbH) and were examined at an 
accelerating voltage of 5 kV and 30 μA emission current. The micrographs were recorded 
digitally using DISS 5 digital image acquisition system (Point Electronic GmbH) [112]. 
Afterwards, particle size distribution was determined by analyzing SEM micrographs using 
ImageJ software (version 1.51q, National Institutes of Health, USA). Mean particle size was 
obtained by measuring the diameter of at least 100 particles. 
2.2.2.4 Preparation of antibacterial and biocompatible nanocoatings 
Small titanium discs (Ti-discs) with definite surface area (1 cm
2
) were cut from a titanium foil 
(0.25 mm thick, annealed, 99.5% (metals basis); Alfa Aesar). Prior to use, the discs were 
thoroughly cleaned using several solvents with the aid of ultrasound bath (Elmasonic P, Elma 
Schmidbauer GmbH). Nano Spray Dryer B-90 (BÜCHI Labortechnik AG) was used to 
produce nanoparticles which will coat the Ti-discs as previously mentioned ( 2.2.2.1). 
The spay drying parameters were kept constant for all formulations: spray cap of 4.0 µm mesh 
diameter (45° angular position), gas flow 100 l/min, spray rate 50%, inlet temperature 70 °C. 
Nano Spray Dryer B-90 was operated in the closed loop mode using nitrogen as drying gas. 
The feed solution was prepared by dissolving norfloxacin (NFX) and PLGA in a solvent 
mixture (acetonitrile and water (95:5) containing 0.005% w/v sodium acetate). Three 
nanocoatings (PLGA 2.5% NFX, PLGA 5% NFX and PLGA 10% NFX) with different 
theoretical norfloxacin loadings (2.5, 5 and 10% wt. of PLGA) were prepared. Unloaded 
nanocoatings (PLGA 0% NFX) were also prepared following the aforementioned procedure 
but without adding norfloxacin. The effect of the disc position on the produced nanocoatings 
was also investigated. Therefore, three different levels inside the particle collector were 
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chosen (i.e. Top, Middle and Bottom) with approx. 6 cm distance between each of them. The 
coating process of the Ti-discs is illustrated in Figure 6. 
 
 
Figure 6 Close-up images from inside the electrostatic particle collector of the Nano Spray 
Dryer B-90 illustrating the coating process of the titanium discs. The star-shaped electrode 
can be observed as well as the titanium discs which were placed at three different positions 
inside the particle collector (i.e. Top, Middle and Bottom). 
2.2.2.5 Morphology and surface structure 
The Morphology and surface structure of the nanocoatings were studied using SEM 
(Hitachi S-510, Hitachi-High Technologies Europe GmbH). The Ti-discs were fixed on 
aluminum pin stubs and sputter-coated with a gold layer (30 mA for 1 min) using 
Edwards S150 Sputter Coater (Edwards Vacuum). The samples were examined at an 
accelerating voltage of 5 kV. The micrographs were recorded digitally using DISS 5 digital 
image acquisition system (Point Electronic GmbH). Afterwards, mean particle size was 
determined by analyzing SEM micrographs using ImageJ software (version 1.47v, National 
Institutes of Health). 
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2.2.2.6 In vitro drug release studies 
Norfloxacin release studies were performed over a period of 15 days under static conditions. 
The coated Ti-discs were placed in 5 ml glass vials (Schott AG) filled with 1 ml PBS (filter-
sterilized, pH 7.4) at 37 °C under light protection. After specific time intervals, 200 µl 
samples were withdrawn and replaced with equivalent volumes of fresh PBS. To avoid 
temperature variations, PBS was also stored at 37 °C under the same conditions. The 
concentration of norfloxacin was quantified by measuring the absorbance at λ = 270 nm using 
a microplate spectrophotometer (Multiskan™ GO, Thermo Scientific). 
2.2.2.7 Nanocoating degradation 
Degradation of nanocoatings under physiological conditions (in terms of pH and temperature) 
was investigated by placing coated Ti-discs in 5 ml tubes (Sarstedt AG & Co. KG) filled with 
1 ml PBS (filter-sterilized, pH 7.4). After 15 days incubation at 37 °C, the discs were 
carefully taken out and dipped thrice in ultrapure water to remove residual PBS. The Ti-discs 
were then left to dry at room temperature under a fume hood. Subsequently, the morphology 
of the nanocoatings were studied using SEM following the same procedure mentioned 
previously ( 2.2.2.5). 
2.2.2.8 Amount of drug per cm2 nanocoating 
The nanocoatings were completely dissolved by placing coated Ti-discs in 24-well plates 
(Standard, F, Sarstedt AG & Co. KG) filled with 1 ml acetonitrile:0.1 M NaOH (1:1) per well. 
The 24-well plates were then gently shaken (150 rpm for 60 min) using an orbital shaker 
(KS4000 IC, IKA Werke GmbH & Co. KG) at room temperature and under light protection. 
Subsequently, the concentration of norfloxacin was quantified by measuring the absorbance at 
λ = 274 nm using a microplate spectrophotometer (Multiskan™ GO, Thermo Scientific). 
2.2.2.9 Agar diffusion test 
The overnight culture of E. coli was used to prepare a bacterial culture with an optical density 
(OD600) of 0.025, which was incubated at 37 °C under gentle shaking (200 rpm) using an 
orbital shaker (Compact Shaker KS 15 A, Edmund Bühler GmbH). To reduce further growth, 
the bacteria were cooled in an ice bath after reaching an OD600 over 0.400. Subsequently, 
100 µl of the bacterial culture were plated on BD
TM
 Mueller Hinton II agar plates 
(BD GmbH). The Ti-discs were then placed in the center of the agar plates (one disc per agar 
plate (Figure 7)). Afterwards, the agar plates were incubated at 37 °C and ~ 90% RH 
(In-VitroCell ES NU-5841E, NuAire, Inc.). After 24 h, the antibacterial activity of the 
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nanocoatings was evaluated by measuring the diameter of the zones of inhibition formed 
around the Ti-discs [113]. Each sample was analyzed in triplicates. 
 
 
Figure 7 Illustration of the agar diffusion test performed with coated titanium discs and 
Mueller Hinton agar plates. 
 
2.2.2.10 Bacterial viability assay 
Antibacterial activity of the nanocoatings was evaluated according to a procedure mentioned 
elsewhere with some modifications [114]. The overnight culture of E. coli was used to 
prepare a bacterial culture with an OD600 of 0.2. 1 ml of this culture was added to 24-well 
plates (Standard, F, Sarstedt AG & Co. KG) containing the Ti-discs. The 24-well plates were 
incubated under static conditions at 37 °C and ~ 90% RH (In-VitroCell ES NU-5841E, 
NuAire, Inc.). After 24 h, the Ti-discs were taken out and immersed thrice in PBS (filter-
sterilized, pH 7.4) to remove non-adherent bacterial cells. The Ti-discs were then transferred 
into new 24-well plates. To detach the bacteria from the surface of the Ti-discs, 1 ml trypsin-
EDTA (5 mg/ml) was added and the samples were gently shaken (100 rpm) at room 
temperature for 20 min using an orbital shaker (Compact Shaker KS 15 A, Edmund Bühler 
GmbH). In order to evaluate the bacterial viability (CFU/cm
2
), different dilutions (1:10 -
 1:1,000,000) of the samples were plated on BD
TM
 Mueller Hinton II agar plates (BD GmbH) 
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and the colonies were counted after 24 h incubation at 37°C and ~ 90% RH (In-VitroCell ES 
NU-5841E, NuAire, Inc.). The samples were analyzed in three independent experiments. 
2.2.2.11 In vitro biocompatibility 
L929 cells were seeded onto 12-well plates (Standard, F, Sarstedt AG & Co. KG) containing 
Ti-discs at a seeding density of 1x10
5
 cells/ 3.65 cm² (per well). After predetermined time 
intervals (i.e. 24 h and 96 h), the Ti-discs were transferred into new 12-well plates and washed 
thrice with PBS containing Ca
2+
 and Mg
2+
 (filter-sterilized, pH 7.4), to remove non-adherent 
cells. For visualizing the cells adhered to the surface of the Ti-discs, the cells were fixed with 
4% formaldehyde solution for 20 min after which the cell nucleus was counterstained with 
DAPI (0.1 µg/ml) for 20 min [99]. Finally, the Ti-discs were mounted onto microscope slides 
and examined under an inverted microscope (CKX53, Olympus Deutschland GmbH) 
equipped with light guide-coupled illumination system (U-HGLGPS, Olympus Deutschland 
GmbH) as fluorescence light source. 
Cell counting experiments were performed according to a procedure mentioned elsewhere 
with some modifications [115]. L929 cells were cultured as mentioned above. After 
predetermined time intervals (i.e. 24 h and 96 h), the Ti-discs were transferred into 24-well 
plates (Standard, F, Sarstedt AG & Co. KG) and washed twice with PBS without Ca
2+
 or 
Mg
2+
 (filter-sterilized, pH 7.4), to remove non-adherent cells. Afterwards, the Ti-discs were 
incubated with EBSS without Ca
2+
 or Mg
2+
 for 10 min at 37 °C. The cells were detached from 
the surface of the Ti-discs using trypsin-EDTA (0.05%). After 10 min incubation at 37 °C, 
DMEM medium (supplemented with 10 % fetal bovine serum) was used to gently wash down 
the cells from the Ti-discs. Finally, 100 µl of the cell suspension were mixed with trypan blue 
solution (1:1) and the viable cells were directly quantified by pipetting 10 µl of this mixture 
into cell counting slide (R1-SLI, Olympus Deutschland GmbH) specially designed for the 
automated cell counter (Cell Counter model R1, Olympus Deutschland GmbH). Each sample 
was analyzed in three independent measurements. 
 
2.2.3 Statistical analysis 
All measurements were performed in triplicates and the values are presented as 
mean ± standard deviation, unless otherwise stated. Two-tailed Student’s t-test was performed 
to identify statistical significance differences. Probability values of p < 0.05 were considered 
significant. 
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3.1 Nano-in-Microparticles for pulmonary applications 
3.1.1 Physicochemical properties of the nanoparticles 
Photodynamic therapy (PDT) is amongst the most rapidly developing therapeutic strategies 
against cancer. With its high safety profile and minimally invasive nature, PDT offers several 
advantages over conventional treatments, which are normally associated with systemic 
toxicity and undesirable side effects [116, 117]. Bronchoscopic PDT is one of the methods 
used in the endoluminal treatment of lung cancer. It involves the administration of a 
photoactive substance (i.e. photosensitizer) followed by illumination of the tumor mass with 
light of a specific wavelength using a flexible fiberoptic bronchoscope. This technique offers 
the advantage of selective cytotoxicity towards tumor cells with minimum damage to the 
surrounding healthy tissues [118]. 
Nevertheless, many photosensitizers suffer from several limitations and drawbacks related to 
off-target toxicity, low water solubility or poor bioavailability. Therefore, researchers have 
been focusing on developing more efficient and selective nanoformulations with controlled 
release properties [119-121]. 
In this work, curcumin was chosen as naturally occurring photosensitizer with diverse 
applications in the field of PDT [122]. Nanoprecipitation method was used to produce 
curcumin loaded nanoparticles, which is a well-established method for preparing PLGA 
nanoparticles with a narrow size distribution and controllable particle size [123]. 
Preliminary experiments were performed to improve the preparation method by optimizing 
the parameters which had significant effect on particle size, dispersity, and encapsulation 
efficiency (e.g. concentration of PLGA, concentration of PVA and curcumin loading). DLS 
and LDV measurements did not indicate any significant effect of curcumin encapsulation on 
particle size, polydispersity index (PdI) or ζ-potential (p > 0.05). Both unloaded and loaded 
nanoparticles had a similar hydrodynamic diameter with monodisperse size distribution 
(PdI ≤ 0.1) and a negative surface charge (Table 5). 
PLGA nanoparticles have been previously reported to have the ability to efficiently 
encapsulate curcumin [97]. Spectrophotometric quantification revealed that 2.5% loading of 
curcumin (%wt of the polymer) is the most appropriate concentration leading to relatively 
high encapsulation efficiency (Table 5). Moreover, when higher curcumin concentrations 
were used (≥ 5%), a yellowish-orange ring appeared on the inside of the beaker. The width of 
the formed ring increased proportionately with increasing the concentration of curcumin due 
CHAPTER III: Results and discussion 
37 
 
to higher amounts of free curcumin that were precipitating on the beaker while evaporating 
the solvent. 
 
Table 5 Particle size distribution, ζ-potential and encapsulation efficiency (EE). 
Formulation Z-Average [nm] PdI ζ-potential [mV] EE [%] 
PLGA.NPs 176.47 ± 13.74 0.10 ± 0.02  -5.07 ± 0.52 - 
PLGA.CUR.NPs 181.20 ± 11.52 0.08 ± 0.02 -4.63 ± 0.13 94.38 ± 0.64 
The values are presented as mean ± standard deviation. 
 
SEM micrographs of PLGA.CUR.NPs showed that the nanoparticles were spherical and had a 
homogenous size distribution with few larger particles which were not detected with DLS 
(Figure 12A). Average particle size was around 160 nm which is slightly smaller than the 
size obtained from DLS measurements. This difference in particle size can be attributed to 
sample preparation and measurement principle since DLS measurements are performed while 
the nanoparticles are still suspended in a dispersant (e.g. water or buffer), whereas in case of 
SEM, the samples are left to dry first [124]. 
3.1.2 Hemocompatibility 
While being transported to the tumor site, the nanoparticles could come in contact with the 
cellular and non-cellular components of blood. Therefore, their hemocompatibility must be 
investigated. Hemolysis assay revealed the influence of nanoparticles on the integrity of 
erythrocytes. Both unloaded and loaded nanoparticles showed minor hemolytic potential 
(Figure 8). Furthermore, aPTT test was performed to study the interaction of nanoparticles 
with intrinsic coagulation factors. Upon addition of nanoparticles, an increase by approx. 9 s 
in the coagulation time was noticed, yet, without serious consequences (Figure 8). 
aPTT values above 70 s are considered to be critical which indicate a spontaneous 
bleeding [125]. Unloaded and loaded nanoparticles exhibited similar hemocompatibility in 
both of aPTT test and hemolysis assay with no significant difference between the observed 
effects (p > 0.05). Negative surface charge of PLGA nanoparticles is one of the key factors 
that granted them good hemocompatibility showing no toxic interactions with blood 
constituents [126]. 
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Figure 8 Hemocompatibility experiments of unloaded nanoparticles (PLGA.NPs) and 
curcumin loaded nanoparticles (PLGA.CUR.NPs). Blank represents untreated erythrocytes in 
hemolysis assay and blood plasma in aPTT test. 
 
3.1.3 Photodynamic activity  
The successful application of curcumin nanoformulations against cancer is well documented 
[108]. Moreover, the combination of curcumin and PDT is a well-proven strategy offering 
higher selectivity towards tumor cells and more localized treatment omitting the need of 
higher doses or longer incubation times [101, 110]. In this study, the photoactivity of the 
nanoparticles was evaluated by measuring their ability to destroy cancer cells upon exposure 
to light of a specific wavelength. As seen in Figure 9, PLGA.CUR.NPs exhibited minimal 
cytotoxicity when the cells were not irradiated (dark). Upon irradiation using an LED device, 
a significant decrease in the cellular viability was observed for both radiation fluence levels. 
The nanoparticles showed a dose-dependent photocytotoxicity and the effective response was 
noticed above certain curcumin dose (>12.5 µM). The half-maximal inhibitory concentration 
(IC50) for curcumin was calculated from the fitted dose-response curves (Figure 10). 
IC50 values were 27.38 µM for 33.03 J/cm
2
 and 17.14 µM for 66.06 J/cm
2
. PLGA.NPs were 
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used as a control and did not exhibit any significant photocytotoxicity regardless of the dose 
or the radiation fluence (Figure 9). 
 
 
Figure 9 Evaluation of the photocytotoxicity of unloaded nanoparticles (PLGA.NPs) and 
curcumin loaded nanoparticles (PLGA.CUR.NPs) in A549 cells. Two different radiation 
fluence levels were tested (i.e. 33.03 and 66.06 J/cm
2) at λ = 457 nm. Dark represents 
unirradiated cells. In case of PLGA.NPs, the x-axis values represent the corresponding 
curcumin concentrations in PLGA.CUR.NPs when equivalent volumes of PLGA.NPs are 
used. 
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Figure 10 Fitted dose-response photocytotoxicity curves of curcumin loaded nanoparticles 
(PLGA.CUR.NPs) in A549 cells (Figure 9). Two different radiation fluence levels were 
tested (i.e. 33.03 and 66.06 J/cm
2) at λ = 457 nm. Dark represents unirradiated cells. 
 
A key factor for an effective PDT is the sufficient cellular uptake of the photosensitizer by the 
target tumor cells [127]. Therefore, CLSM was used to visualize the intracellular localization 
of curcumin after incubating the nanoparticles with A549 cells for 4 h. High fluorescence 
intensity was observed confirming the successful uptake of PLGA.CUR.NPs with curcumin 
mostly localized near the cell nucleus (Figure 11B). Upon irradiation, more intensive and 
distributed fluorescence was observed (Figure 11D) in comparison with unirradiated cells 
indicating further release of curcumin from the nanoparticles [110]. 
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Figure 11 CLSM images of A549 cells incubated with unloaded nanoparticles (PLGA.NPs) 
and curcumin loaded nanoparticles (PLGA.CUR.NPs). Radiation fluence used was 
33.03 J/cm
2
 at λ = 457 nm. Dark represents unirradiated cells. The cell nucleus (blue) was 
counterstained with DAPI. Scale bars represent 20 µm. 
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3.1.4 Physicochemical properties of the Nano-in-Microparticles 
A suitable route of administration must be chosen, so that the photosensitizer reaches its target 
tissue and accumulates in therapeutic concentrations. Although PDT has been effectively 
applied against several types of lung cancer [128], intravenous administration is still the route 
of choice for most of the clinically approved photosensitizers with only a few reports about 
pulmonary drug delivery in this field [129]. This issue raises the need of photosensitizer 
loaded nanoformulations which could exploit the numerous advantages of the lungs such as: 
being non-invasive route of administration, a lower administered dose and minimum systemic 
exposure of drug intended for local application [34]. 
In this regard, the photosensitizer loaded nanoformulation which was previously prepared 
in  2.2.1.1 (i.e. PLGA.CUR.NPs) was spray dried with a sugar matrix (mannitol) to be 
transformed into a dry powder for inhalation in the form of Nano-in-Microparticles (NiMps). 
The spray drying parameters were optimized to achieve high powder yield and enhanced 
aerodynamic properties, taking into consideration the physical properties of PLGA, especially 
the glass transition temperature. After collecting the spray dried product, yield% was 
calculated and found to be 54.80 ± 4.21 %. This is considered a very good product yield 
which can be related to the use of high-performance cyclone which facilitated the recovery of 
a high amount of the spray dried product [13]. Mannitol was chosen as matrix excipient due to 
its suitability for pulmonary applications and it has been already used in FDA approved 
pharmaceutical preparations (e.g. Exubera®) [130]. Moreover, mannitol has a high aqueous 
solubility which is essential for the disintegration of the microparticles to release the 
nanoparticles once they are deposited in the lungs. Other matrix excipients have been also 
used in the preparation of inhalable formulations based on curcumin loaded PLGA 
nanoparticles [65]. However, using polycationic polymers like chitosan as matrix substance 
will lead to electrostatic interactions with the anionic lipids in the lung surfactant and 
critically influencing their surface activity [131, 132]. 
Redispersibility of NiMps was evaluated by redispersing the sprayed powder in water. 
DLS measurements of the redispersed nanoparticles revealed a particle size of 
233.41 ± 24.22 nm and PdI of 0.23 ± 0.03. This increase in particle size and PdI could be due 
to slight aggregation caused by shear forces during the atomization step [61]. Even after 
storage for almost five months, NiMps were readily dispersible, confirming the benefit of 
spray drying in improving long-term stability of the nanoparticles. Furthermore, mannitol 
plays a vital role in increasing the space between the nanoparticles which will reduce 
particle-particle interactions and improve the disintegration of the microparticles [56]. 
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SEM micrographs of NiMps (Figure 12B and C) showed raisin-like particles with wrinkled 
morphology and relatively broad particle size distribution ranging from 0.5 to 4 µm. 
The particle size and morphology of NiMps are mainly determined by the mass ratio of 
nanoparticles to mannitol. Increasing the nanoparticles content will lead to the formation of 
less spherical and more collapsed particles [72]. 
 
 
Figure 12 SEM micrographs showing the morphology of A: curcumin loaded PLGA 
nanoparticles, B and C: Nano-in-Microparticles. D: CLEM image consisting of SEM 
micrograph of Nano-in-Microparticles merged with the fluorescence signal (yellow) of 
curcumin loaded nanoparticles from CLSM. 
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Additional details about NiMps structure were obtained from CLEM imaging which served as 
a confirmation of the nanoparticle distribution within the microparticles (Figure 12D). 
Moreover, using CLSM, it was also possible to confirm the ability of mannitol to embed 
nanoparticles homogenously by analyzing each fluorescence channel separately since the 
nanoparticles were loaded with curcumin and mannitol was labeled with rhodamine B 
(Figure 13). Previous studies reported similar results with mannitol and different types of 
nanoparticles [62, 72]. 
 
 
Figure 13 CLSM images showing the morphology of the Nano-in-Microparticles and the 
homogenous distribution of curcumin loaded nanoparticles (PLGA.CUR.NPs) within the 
matrix substance (i.e. mannitol). Scale bars represent 10 µm. 
 
3.1.5 Aerodynamic properties and lung compatibility 
The pulmonary deposition of inhaled particles is significantly controlled by their aerodynamic 
properties. An aerodynamic diameter between 1 to 5 µm will help achieving higher particle 
deposition in the lung especially in the lower airways [55]. NiMps were characterized using 
NGI which is one the devices recommended by the European Pharmacopeia for aerodynamic 
assessment of fine particles (Chapter 2.9.18). NiMps exhibited good aerosolization behavior 
with MMAD of 3.02 ± 0.07 µm within the desirable range and high FPF (64.94 ± 3.47%) 
(Figure 14). GSD was found to be 1.74 ± 0.16 indicating a polydisperse powder which was 
also noticed in SEM micrographs. This GSD value, however, falls within the typical range for 
most pharmaceutical aerosols (1.5 - 2.5) [133]. NGI results proved the ability of NiMps to 
deliver the nanoparticles efficiently to the lungs omitting the need of additional excipients like 
coarse carrier particles (e.g. lactose) or aerosolization enhancer (e.g. amino acids). 
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Following deposition, NiMps will come in contact with lung fluids. Depending on their 
deposition site, the particles have to pass the mucus blanket within the airways or pulmonary 
surfactant layer lining the alveolar epithelium to reach their target [52]. In this regard, the 
interaction of NiMps with a monolayer of bovine lung surfactant (Alveofact®) was 
investigated using Langmuir film balance. Two different surface pressures were used to 
simulate the interaction of PLGA.CUR.NPs with pulmonary surfactant during the breathing 
process [134]. The pure monolayers were in continuous phase at those pressures. Figure 15 
shows the π-t isotherm of pure Alveofact® dynamically compressed up to a surface pressure 
of 25 mN/m (A) and 42 mN/m (B) at a velocity of 20 cm
2
/min. 
 
 
Figure 14 The distribution of Nano-in-Microparticles on different parts of the next generation 
impactor. Mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD) 
and fine particle fraction (FPF) were also calculated. Values are presented as mean ± standard 
deviation.  
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After reaching the desired surface pressure, the barriers were stopped so that the Alveofact® 
monolayer could equilibrate. The properties of the Alveofact® monolayer were then 
monitored for 60 min. Directly after the barriers stopped, the π-t isotherms of pure 
Alveofact® decreased by 1–2 mN/m. This was caused by a new array of lipids in the 
monolayer after the dynamic compression or due to other processes like relaxation and 
desorption [135]. Subsequently, the monolayer equilibrated and the surface pressures 
stabilized. The gray curves represent the π-t isotherms where 20 µl of PLGA.CUR.NPs were 
added 15 min after the barriers were stopped. After the injection of the nanoparticles, no 
change in the π-t isotherm could be observed at both tested surface pressures, suggesting no 
substantial interaction between the nanoparticles and surfactant. In other words, integration of 
the nanoparticles into the surfactant monolayer would have caused an increase in the surface 
pressure over time, and vice versa, a decrease in the surface pressure would mean that the 
nanoparticles have either withdrawn the compounds out of the monolayer or destroyed 
it [102]. These outcomes confirmed that NiMps with all their components (nanoparticles and 
mannitol) are compatible with pulmonary surfactant at physiological pressures. 
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Figure 15 π-t (surface pressure-time) isotherms showing the interaction of curcumin loaded 
nanoparticles (PLGA.CUR.NPs) with a monolayer of bovine lung surfactant (Alveofact®) 
using Langmuir film balance. The surface pressures were increased up to 25 mN/m (A) and 
42 mN/m (B). After an equilibration time of 15 min, PLGA.CUR.NPs were injected into the 
subphase. 
  
CHAPTER III: Results and discussion 
48 
 
3.2 Nano spray drying for coating of medical implants 
3.2.1 Preliminary experiments 
Coating and surface modification of medical implants with nanoparticles offers several 
advantages. Nanoparticulate systems can serve as a multifunctional coating which can act as 
drug depot with different release profiles. Moreover, nanoparticles can alter the surface 
morphology of the implants to prevent bacterial adhesion and even improve healing rate [136-
138]. Nanoparticles have various forms and can be produced by several methods using natural 
or synthetic polymers. They have shown valuable utilizations in all aspects of life, especially 
as drug delivery systems. Nanoscale drug carriers have been employed to overcome numerous 
limitations and improve the efficiency of many active pharmaceutical ingredients, 
e.g. solubility enhancement, targeted drug delivery and controlled release [123, 139]. 
In this work, a novel approach for producing biocompatible nanoscale coatings using the 
Nano Spray dryer B-90 was introduced. Therefore, three model substances were chosen to 
represent three various categories of biomaterials; water soluble polymers, water insoluble 
polymers and pure drugs. For this purpose, chitosan, PLGA and curcumin were considered. 
The spray drying parameters were set to produce the smallest particle size possible taking into 
consideration the physicochemical properties of the chosen model substances (e.g. viscosity 
of chitosan solution, glass transition temperature of PLGA). Therefore, low solid 
concentration of the sprayed sample (0.1%) and the smallest available size of the spray mesh 
(4.0 µm) were used. Previous studies have confirmed that the solid concentration of the 
sprayed sample and the size of the spray mesh are the most critical parameters with the 
strongest influence on the particle size of the produced particles [60, 85, 140]. 
However, the effect of the implant position inside the particle collector and the required 
amount of the sprayed sample should also be optimized. Therefore, preliminary experiments 
were performed on titanium plates which were placed at three different positions inside the 
electrostatic particle collector. Initially, 15 ml samples were tested. This amount was found to 
be insufficient to get a complete coverage of the titanium plates. Subsequently, 50 ml samples 
were tried and found to be adequate. These findings indicated that only a small quantity of the 
sprayed substance (50 mg) was needed to achieve a successful coating even in the plates 
positioned at the bottom of the collector. This is one of the advantages of the Nano Spray 
Dryer B-90 that was originally developed for early stage research where larger amounts of the 
sample are hard to obtain [86, 140]. 
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SEM micrographs revealed that the produced particles in all experiments were spherical and 
had a smooth surface. The titanium plates at the top part of the collector were covered with 
more particles which formed multilayer coating (Figure 16 Top). Moreover, the particle size 
analysis showed that the particle size distribution for all formulations on this level was 
heterogeneous and the mean particle size was around 600 nm in case of chitosan and around 
900 nm in case of PLGA and curcumin (Figure 17 Top). On the other hand, the results of the 
bottom plates clearly showed that there is a significant decrease in the particle size 
distribution. It was also noticed that the plates on the bottom part of the collector had almost 
the same mean particle size but a narrower size distribution in comparison with the plates on 
the top part which correlated with previous studies [85]. Interestingly, in case of PLGA and 
curcumin the mean particle size decreased and a considerable number of smaller nanoparticles 
(around 300 nm) was also observed (Figure 17 Bottom). These results can be explained by 
the fact that larger particles have a higher surface charge and therefore get captured easily by 
the particle collector than smaller particles [85, 95, 141]. 
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Figure 16 SEM micrographs showing the coating of titanium plates with three different 
substances; chitosan, PLGA and curcumin. The titanium plates were placed at three different 
positions inside the particle collector (i.e. Top, Middle and Bottom). Scale bars represent 
A: 20 µm and B: 5 µm. 
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Figure 17 Particle size analysis of the SEM micrographs of titanium plates coated with 
chitosan, PLGA and curcumin respectively (Figure 16). 
 
Finally, the optimized parameters were applied to dental implants which were used in this 
study as an example of small medical implants. The implants were positioned 12 cm towards 
the bottom of the particle collector as this position was found to be the best to completely coat 
the implant with the smallest particles. The visual inspections with stereomicroscope and 
CLSM provided a confirmation about a successful and homogenous coating by comparing the 
coated implant with unmodified one (Figure 18). SEM results of the implants were 
comparable with the titanium plates that were placed at the bottom part of the collector 
(Figure 19). According to particles size analysis, all implants were successfully coated with 
particles that were in the range of 300 nm – 1.5 µm with a mean particle size of 500 nm 
(Figure 20). 
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Figure 18 Stereomicroscope images (left) of the dental implants (apical view) before and 
after spray drying. Inset CLSM images (right) of the coated implants indicating coating 
uniformity. Scale bars represent 100 µm. 
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Figure 19 SEM micrographs showing successful coating of the dental implants with chitosan, 
PLGA and curcumin, respectively. A: shows the surface structure of one of the implant roots 
between two crests. B and C: show the surface morphology of the apical part of the implant. 
Scale bars represent A: 70 µm, B: 20 µm, C: 5µm 
 
Figure 20 Particle size analysis of the SEM micrographs of dental implants coated with 
chitosan, PLGA and curcumin respectively (Figure 19).  
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3.2.2 Antibacterial and biocompatible nanocoatings 
3.2.2.1 Morphology and surface properties 
In the preliminary experiments, nano spray drying exhibited such promising potentials as a 
novel approach to prepare nanoscale coatings for dental implants. The wide range 
applicability of this technique was confirmed using three different model substances with 
different physicochemical properties, i.e. chitosan, PLGA and curcumin. The next step was to 
explore the capability of this coating technique to produce biocompatible nanocoatings with 
antibacterial activity. Therefore, PLGA-based nanocoatings were produced using norfloxacin 
as a model drug for broad-spectrum antibacterial agents [142-145]. The optimized spray 
drying process parameters from the preliminary experiments were applied on Ti-discs, taking 
into consideration previous studies, wherein the spray mesh size and the solid concentration 
of the feed solution had the most pronounced influence on the size of the produced particles 
[60, 86, 140]. Therefore, all formulations were prepared with low solid concentration 
(1 mg/ml) and the smallest spray mesh available (4.0 µm) was used, thereby achieving the 
smallest possible particle size. Due to its crucial role in controlling the properties of the 
produced nanocoatings, disc position inside the particle collector was investigated. Therefore, 
Ti-discs where fixed at three different positions (i.e. Top, Middle and Bottom). 
SEM micrographs of the Ti-discs (Figure 21) were similar to those of the preliminary 
experiments (Figure 16). All produced particles were spherical and had a smooth surface. 
At the top part of the collector, the Ti-discs were covered with multilayered nanocoatings 
consisted of single particles and nanostructured microaggregates (Figure 21 Top). On the 
contrary, the Ti-discs at the bottom part were coated with a monolayer of single particles with 
no obvious presence of any aggregates (Figure 21 Bottom). Particle size analysis of the SEM 
micrographs revealed an average particle size around 600 nm for the nanocoatings at the top 
part of the collector with relatively broad particles size distribution and significant number of 
microparticles (Figure 22 Top). Interestingly, at the bottom part a substantial decrease in the 
particle size was observed (around 400 nm) with a more homogenous size distribution 
wherein most of the particles were in the submicron range (Figure 22 Bottom). 
These results can be explained based on the fact that bigger particles carry higher surface 
charge; therefore, they get captured easily by the electrostatic particle collector [85, 95, 141]. 
Thus, as the dried particles moves downward, they will be fractionated along the electrostatic 
particle collector thereby having the smallest particles with the narrowest size distribution at 
the bottom part of the collector. 
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It is noteworthy that SEM results revealed no significant difference between unloaded 
nanocoatings (PLGA 0% NFX) and norfloxacin loaded nanocoatings (PLGA 5% NFX) in 
terms of morphology and particle size distribution. 
 
 
Figure 21 SEM micrographs of coated titanium discs showing the morphology and surface 
structure of unloaded nanocoatings (PLGA 0% NFX) and norfloxacin loaded nanocoatings 
(PLGA 5% NFX). The titanium discs were fixed at three different positions inside the 
electrostatic particle collector (i.e. Top, Middle and Bottom). Scale bars represent 5 µm. 
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Figure 22 Particle size analysis based on the SEM micrographs of unloaded nanocoatings 
(PLGA 0% NFX) and norfloxacin loaded nanocoatings (PLGA 5% NFX) (Figure 21). 
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3.2.2.2 In vitro drug release studies 
Nano spray drying has been successfully utilized in several studies for the preparation of 
PLGA submicroparticles that exhibited controlled drug release properties [60, 89, 92, 95].  
Drug release rate was found to be influenced by several factors e.g. particle size [96], 
PLGA lactide:glycolide ratio and molecular weight [89]. 
In this work, the release profile of several nanocoatings was studied over a period of 15 days 
in PBS (pH 7.4) at 37 °C. To investigate the effect of theoretical drug loading on the release 
behavior, Ti-discs placed at the same level inside the particle collector (i.e. Top); however, 
with three different theoretical norfloxacin loadings (i.e. 2.5%, 5% and 10%) were examined 
(Figure 23). Furthermore, the influence of Ti-disc position inside the particle collector was 
also explored; therefore, Ti-discs with the same norfloxacin loading (i.e. 5%); however, 
placed at three different levels inside the particle collector (i.e. Top, Middle and Bottom) were 
tested (Figure 24). All nanocoatings exhibited similar release profiles that are typically 
observed with PLGA nano-/microparticles encapsulating hydrophobic drugs [136]. 
By observing the release graphs especially (Figure 23 A) and (Figure 24 C), the release 
profiles could be divided into two phases. In the first 48 h, an initial burst release was 
observed, which can be mainly due to drug desorption from the nanocoatings surface [146, 
147]. Moreover, the sharp peak noticed in all graphs after 1 h incubation can be also attributed 
to the fast dissolution of free nonencapsulated drug [148]. This “burst phase” was found to be 
directly influenced by the theoretical norfloxacin loading and it was most obvious at the 
highest norfloxacin loading (i.e. 10%) which is in agreement with previous studies [147]. 
Starting from the third day until the end of experiment period, a second phase was noticed, 
wherein norfloxacin was released at low but constant rate. According to previous studies, drug 
diffusion is the main release mechanism at this phase, possibly through the matrix of PLGA 
particles or water-filled pores [147-149]. However, drug release from PLGA formulations is a 
very complex process; therefore, other mechanisms might be also controlling the release at 
this phase [148]. This sustained release phase did not seem to be influenced by theoretical 
norfloxacin loading or Ti-disc position inside the particle collector. It is worth mentioning that 
no secondary burst release was observed during the test period. 
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Figure 23 In vitro release profile of norfloxacin over a period of 15 days in PBS (pH 7.4) at 
37 °C. In this experiment, the coated titanium discs were fixed at the same level inside the 
particle collector (i.e. Top); however, with three different theoretical norfloxacin loadings  
(i.e. 2.5%, 5% and 10%). A: The released amount of norfloxacin after different time intervals. 
B: Cumulative release profile of norfloxacin. 
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Figure 24 In vitro release profile of norfloxacin over a period of 15 days in PBS (pH 7.4) at 
37 °C. In this experiment, the coated titanium discs had the same theoretical norfloxacin 
loading (i.e. 5%); however, they were fixed at three different levels inside the particle 
collector (i.e. Top, Middle and Bottom). A: The released amount of norfloxacin after different 
time intervals. B: Cumulative release profile of norfloxacin. 
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3.2.2.3 Nanocoating degradation 
SEM was used to investigate the degradation of nanocoatings and the possible morphological 
changes they might experience after 15 days incubation in PBS (pH 7.4) at 37 °C.  
SEM micrographs showed that all examined nanocoatings (PLGA 0% NFX and 
PLGA 5% NFX) remained adhered to the surface of Ti-discs which was in agreement with 
previous studies [136]; however, substantial changes in the morphology and surface structure 
were observed (Figure 25). Most particles were deformed and had corrugated surface. 
Significant number of aggregates was noticeable even in the Bottom level which was not the 
case before incubation in PBS. Interestingly, some particles lost their structure completely and 
were merged together forming sort of porous film. This phenomenon was obvious in all 
levels, especially Top and Middle where it appeared as a net-like structure. 
Previous studies have related the causes of PLGA particles aggregation and deformation to 
the fact that PLGA polymer starts to degrade by means of hydrolysis upon contact with the 
incubation medium (i.e. PBS). As the degradation process continues, the molecular weight 
decreases causing a drop in the glass transition temperature (Tg). When the Tg reaches a 
critical value below the temperature of incubation medium (i.e. 37 °C), PLGA polymer will 
be in the rubbery state and become more flexible. Consequently, PLGA particles start to 
aggregate and lose their spherical shape [150-152]. 
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Figure 25 SEM micrographs of the unloaded nanocoatings (PLGA 0% NFX) and norfloxacin 
loaded nanocoatings (PLGA 5% NFX) after 15 days incubation at 37 °C in PBS (pH 7.4). 
The titanium discs were fixed at three positions inside the electrostatic particle collector 
(i.e. Top, Middle and Bottom). Scale bars represent 5 µm. 
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3.2.2.4 Antibacterial activity 
Agar diffusion test is one of the standard methods commonly used for antimicrobial 
susceptibility testing [113]. In this study, E. coli was chosen as a model organism to evaluate 
antibacterial activity of the nanocoatings wherein the influence of the theoretical norfloxacin 
loading and Ti-disc position inside the particle collector were investigated (Figure 26). 
This approach served as a first step to explore the most suitable variant among different 
nanocoatings and reduce the number of samples. As expected, the largest zones of inhibition 
were observed in PLGA 10% NFX; however, they were comparable to those of 
PLGA 5% NFX. Moreover, at these loadings (i.e. 10% and 5%), Ti-disc position inside the 
particle collector did not have a pronounced influence on the zones of inhibition. A significant 
decrease in the zones of inhibition was noticed in PLGA 2.5% NFX, especially Middle and 
Bottom. PLGA 0% NFX were used as negative control and did not show any antibacterial 
activity. Since the bacterial growth inhibition is related to the amount of antibiotic diffused 
through the agar [113], a direct relationship between norfloxacin content in the nanocoatings 
and the size of the zones of inhibition could be seen. Spectrophotometric quantification 
showed that norfloxacin loading and Ti-disc position inside the particle collector significantly 
controlled the amount of norfloxacin per cm
2
 of the nanocoating (Figure 27). This can be 
attributed to the particle fractionation effect along the particle collector previously observed in 
SEM micrographs (Figure 21), wherein Ti-discs at the top part were covered with more and 
larger particles in comparison to those at the bottom part. As a result, the produced 
nanocoatings had a norfloxacin content ranged between 10.33 µg/cm
2
 (PLGA 10% NFX Top) 
and 0.73 µg/cm
2
 (PLGA 2.5% NFX Bottom). 
Based on the results of in vitro release studies and agar diffusion test, PLGA 5% NFX were 
chosen for further characterizations. They were found to be more efficient in comparison to 
other nanocoatings (i.e. 2.5% and 10%), exhibiting similar release profiles and sufficient 
antibacterial activity, yet without the need of higher norfloxacin loading. 
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Figure 26 Summary of the results of agar diffusion test, wherein E. coli suspension was 
plated on Mueller Hinton agar plates and incubated with the coated titanium discs for 24 h at 
37 °C. Nanocoatings with three different theoretical norfloxacin loadings (PLGA 2.5% NFX, 
PLGA 5% NFX and PLGA 10% NFX) were tested. Unloaded nanocoatings (PLGA 0% NFX) 
were used as a negative control. Top, Middle and Bottom indicate the position of the titanium 
discs inside the particle collector. The zones of inhibition formed around the titanium discs 
could be clearly observed, indicating the antibacterial activity of the nanocoatings. 
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Figure 27 Graphical representation of the relationship between the amount of norfloxacin 
per cm
2
 of the nanocoating (bars) and the diameter of the zone of inhibition (dots). 
Nanocoatings with three different theoretical norfloxacin loadings (PLGA 2.5% NFX, 
PLGA 5% NFX and PLGA 10% NFX) were tested. The titanium discs were fixed at three 
positions inside the electrostatic particle collector (i.e. Top, Middle and Bottom). 
 
Since agar diffusion test deliver mainly qualitative results [153], further in vitro bacterial 
investigations with the chosen nanocoatings (i.e. PLGA 5% NFX) were performed to get a 
precise evidence about their antibacterial activity. Therefore, the coated Ti-discs were 
incubated with E. coli suspension for 24 h and the adhered bacteria were thereafter quantified. 
PLGA 5% NFX caused a significant reduction in the bacterial viability in comparison to 
uncoated Ti-discs (p < 0.05). This reduction ranged between 99.83% (PLGA 5% NFX Top) 
and 95.42% (PLGA 5% NFX Bottom) (Figure 28). 
PLGA 0% NFX did not exhibit any considerable influence on the bacterial viability (p > 0.05) 
regardless of the Ti-disc position inside the particle collector. Hence, the antibacterial activity 
of PLGA 5% NFX can be attributed only to norfloxacin without any pronounced influence 
from the surface structure of the nanocoatings. 
 
 
 
CHAPTER III: Results and discussion 
65 
 
 
Figure 28 Evaluation of in vitro antibacterial activity of unloaded nanocoatings 
(PLGA 0% NFX) and norfloxacin loaded nanocoatings (PLGA 5% NFX). The titanium discs 
were fixed at three positions inside the electrostatic particle collector (i.e. Top, Middle and 
Bottom). Uncoated titanium discs were used as negative control. E. coli viability is presented 
as colony-forming unit per cm
2
 of the titanium discs. The asterisk denotes probability values 
of p < 0.05 which were considered statistically significant.  
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3.2.2.5 In vitro biocompatibility 
The nanocoating biocompatibility was evaluated using L929 cells as a standard sensitive cell 
line for assessing in vitro cytotoxicity [98, 154]. The cell growth on the surface of the 
Ti-discs was qualitatively and quantitatively studied over a period of 4 days. 
First, the cells were visualized using fluorescence microscopy wherein the cell nucleus was 
counterstained with DAPI (Figure 29). All examined samples (i.e. uncoated Ti-discs, 
PLGA 0% NFX and PLGA 5% NFX) exhibited comparable results. A substantial increase in 
the cell number could be observed in the fluorescence micrographs of the Ti-discs after 96 h 
incubation where the cells covered most of the surface. These results gave only a visual 
confirmation of the nanocoating biocompatibility. Therefore, a quantitative assessment was 
still needed to understand the influence of norfloxacin loading and Ti-disc position inside the 
particle collector on the nanocoating cytotoxicity. 
This was achieved by counting the number of cells adhered to the surface of Ti-discs after 
24 h and 96 h incubation (Figure 30). Cell counting results of all samples after 24 h 
incubation were remarkably close with no significant difference between the coated 
(PLGA 0% NFX and PLGA 5% NFX) and the uncoated Ti-discs (p > 0.05). As seen 
previously in the visualization experiments, the cell number increased considerably in all 
samples after 96 h incubation. The number of the cells adhered to the coated (all nanocoatings 
except PLGA 5% NFX Top) and the uncoated Ti-discs was comparable (p > 0.05) indicating 
a good biocompatibility of the nanocoatings which did not exert any serious toxic effect that 
might influence the cell proliferation. These results are in agreement with previous studies 
which reported the use of PLGA nanoparticles as biocompatible coatings for medical implants 
[98, 115]. 
The only noticed cytotoxicity was with PLGA 5% NFX Top which resulted in suboptimal cell 
growth when compared to the uncoated Ti-discs (p = 0.04). This could be related to the high 
norfloxacin content in the nanocoating which might have adversely affected the cell 
proliferation. These findings indicated the importance of adjusting the drug content in the 
nanocoatings to achieve a balance between the desired therapeutic effect and the cytotoxicity. 
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Figure 29 Fluorescence microscope images showing the growth of L929 cells on titanium 
discs after 24 h and 96 h incubation. A: uncoated discs, B: unloaded nanocoatings 
(PLGA 0% NFX), C: norfloxacin loaded nanocoatings (PLGA 5% NFX). The titanium discs 
were fixed at three positions inside the electrostatic particle collector (i.e. Top, Middle and 
Bottom). The cell nucleus (blue) was counterstained with DAPI. Scale bars represent 20 µm.  
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Figure 30 Number of cells adhered to the surface of the titanium discs after 24 h and 96 h 
incubation. Cell counting assay were performed using mouse fibroblasts (L929) where 
unloaded nanocoatings (i.e. PLGA 0% NFX) and norfloxacin loaded nanocoatings 
(PLGA 5% NFX) were tested. The titanium discs were fixed at three positions inside the 
electrostatic particle collector (i.e. Top, Middle and Bottom). Uncoated titanium discs were 
used as a negative control. 
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3.2.3 Coating of coronary stents 
In the preliminary experiments, the preparation of nanoscale coatings using nano spray drying 
was developed on titanium plates which were used as a model material for dental implants.  
To investigate the potentials of this coating technique on a different type of medical implants, 
coronary stents made of stainless steel were used (Camouflage® coronary stent system, 
balloon diameter 2.5 mm, stent length 18 mm). The stent was fixed on the bottom part of the 
electrostatic particle collector (approx. 12 cm) and the nanocoatings were produced under the 
same conditions previously mentioned ( 2.2.2.4). PLGA was used as a model substance due to 
its interesting biodegradability and biocompatibility that made him one of the most commonly 
used polymers in the preparation of nanoparticle-eluting stents [155-157]. 
SEM micrographs of different parts of the coated stent showed a uniform coverage of the 
stent surface with PLGA nanocoatings even hard-to-reach areas (Figure 31). The produced 
particles formed a single layer and their morphology varied between spherical and irregular 
shape with a relatively wide particle size distribution. 
These findings were to a great extent in agreement with those observed in dental implants, 
confirming the feasibility of utilizing nano spray drying as a promising approach for the 
coating and surface modification of different types of medical implants even those with 
challenging topography. 
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Figure 31 SEM micrographs of PLGA nanocoatings prepared using nano spray drying for the 
surface modification of coronary stent which was fixed approx. 12 cm towards the bottom 
part of the electrostatic particle collector. A: General view of the coated stent. B and C: Closer 
views showing detailed surface morphology of different parts of the coated stent. Scale bars 
represent A: 400 µm, B: 40 µm, C: 5 µm. 
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4.1 Summary and outlook 
Spray drying is a well-established method for the transformation of liquid formulations into 
dried particles. This technique is still gaining increasing interest due to its numerous 
advantages and wide range of applications. Furthermore, the emergence of nano spray drying 
in the last decade, took the capabilities of spray drying to the next level, especially in the field 
of nanoparticle production. 
This thesis comprises detailed studies on the applications of spray drying in two important 
fields: pulmonary drug delivery and coating of medical implants. 
 
The first objective was to employ spray drying in developing an inhalable photosensitizer 
loaded formulation for the bronchoscopic photodynamic therapy (Figure 32). Pulmonary 
administration of photosensitizers will help achieving both selective and completely non-
invasive treatment against lung cancer. Thus, offering a promising alternative to the 
intravenous route and achieving better patient compliance. 
 
 
Figure 32 Graphical abstract summarizing the first objective of this thesis. 
 
Curcumin was chosen as a naturally occurring photosensitizer; however, its low water 
solubility and poor bioavailability were the main drawbacks. Therefore, curcumin 
nanoparticles were prepared using the nanoprecipitation method to enhance its efficacy 
against tumor cells. According to dynamic light scattering measurements, curcumin 
nanoparticles had a homogenous size distribution and a particle size suitable for cellular 
uptake. The prepared nanoparticles exhibited a good hemocompatibility with minor hemolytic 
potential and no critical influence on coagulation time. In vitro irradiation experiments using 
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human lung epithelial carcinoma cells (A549) revealed an effective photoresponse of 
curcumin nanoparticles as they were able to destroy cancer cells upon activation with a light 
of specific wavelength using LED irradiating device. Moreover, curcumin nanoparticles 
exhibited a dose-dependent photocytotoxicity and the IC50 values of curcumin were directly 
dependent on the radiation fluence used. 
Nano-in-Microparticles were produced by spray drying curcumin nanoparticles with 
mannitol, thereby transforming the nanoparticles into a dry powder for inhalation without 
experiencing drastic conditions. The aerodynamic properties of the Nano-in-Microparticles 
were investigated using the next generation impactor which revealed a large fine particle 
fraction and an appropriate mass median aerodynamic diameter for a sufficient deposition in 
the lungs. The Nano-in-Microparticles exhibited a good redispersibility and disintegrated into 
the original nanoparticles upon redispersion in aqueous medium. This can be attributed to 
mannitol which was used as the wall material embedding the nanoparticles to keep them 
intact during the drying process and facilitate their release from the microparticles.  
Langmuir monolayer experiments confirmed the compatibility of the Nano-in-Microparticles 
with the pulmonary surfactant which is an important prerequisite for the safe delivery of 
curcumin to its site of action in the lungs (i.e. tumor cells). 
These results demonstrated the feasibility of spray drying for preparing inhalable drug carriers 
with promising potentials in the field of photodynamic therapy. In vivo studies should be the 
next step in order to evaluate the ability of these formulations to overcome the biological 
barriers of the lung. Furthermore, an accurate dosage assessment must be performed to 
achieve an effective therapy. 
 
The second objective was to introduce nano spray drying as a novel technique for the 
preparation of nanoparticles of different biomaterials that are capable of modifying the 
surface structure of medical implants even those with a challenging topography (Figure 33) 
The Nano Spray Dryer B-90 with its unique advanced features, facilitated particles production 
and implant coating in a single step omitting the need of additional drying or washing steps.  
This newly developed coating technique will offer several advantages: a) the ability to 
produce particles in the submicron range from the pure substance solution without any 
additives (e.g. surfactants) or time-consuming complex modifications; b) very gentle process 
conditions that are suitable even for sensitive and thermolabile substances (e.g. enzymes, 
hormones and nucleic acids); c) this technique is highly efficient and cost-effective, since a 
small amount of the sample is needed to achieve the best results; d) the unique cylindrical 
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shape and functional principle of the particle collector enable a stable spatial surface coating, 
making upscaling easily applicable since it is possible to fix several implants on the particle 
collector to be coated simultaneously. 
 
 
Figure 33 Graphical abstract summarizing the second objective of this thesis. 
 
In this thesis, the wide range applicability of this coating technique has been demonstrated by 
testing three representative model substances, namely chitosan, poly(lactic-co-glycolic acid) 
and curcumin. Preliminary experiments were performed on titanium plates to optimize the 
process parameters, thereby achieving small particle size, narrow size distribution and 
complete coverage of the implants. The optimized parameters were thereafter successfully 
applied on dental implants and the coating homogeneity was confirmed using fluorescence 
microscopy. Scanning electron microscope images showed that most of the produced particles 
were in the submicron range and had a spherical shape with a smooth surface. Particle size 
analysis indicated the influence of the implant position inside the particle collector on the 
particle size distribution where the bottom part of the collector had the particles with the 
narrowest size distribution. 
These findings paved the way for preparing biocompatible nanocoatings with antibacterial 
activity. The optimized process parameters from the preliminary experiments were applied on 
titanium discs, which were used as a model material for dental implants. The produced 
nanocoatings consisted of poly(lactic-co-glycolic acid) as a biodegradable polymer and 
norfloxacin as a model antibiotic. Scanning electron microscopy results of the nanocoatings 
were similar to those of preliminary experiments in terms of particle size distribution, 
morphology and surface structure which confirmed the reproducibility of this coating 
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technique. The nanocoatings exhibited a typical biphasic drug release profile with a burst 
release in the first 48 h, followed by sustained release phase until the end of experiment. 
Antibacterial activity of the nanocoatings was evaluated against Escherichia coli in two 
stages: first, qualitatively, using agar diffusion test which facilitated the examination of large 
number of samples, and then quantitatively, by counting the number of viable bacterial 
colonies adhered to the surface of the titanium discs. The antibacterial activity of the 
norfloxacin loaded nanocoatings was evident and could be observed either as zone of 
inhibitions (agar diffusion test) or as a significant reduction in the number of viable bacterial 
colonies (quantification experiments). This activity was directly dependent on the norfloxacin 
content in the nanocoatings which was influenced by the theoretical norfloxacin loading and 
the titanium disc position inside the particle collector. Finally, in vitro biocompatibility of the 
nanocoatings was investigated using mouse fibroblasts (L929) as a standard sensitive cell line 
for cytotoxicity assessment. Cell proliferation on the surface of the titanium discs was studied 
using fluorescence microscopy followed by cell counting assay. Both methods confirmed the 
biocompatibility of the examined nanocoatings which exhibited similar results when 
compared to the uncoated titanium discs. 
Although nano spray drying has shown such interesting potentials for preparing novel 
nanocoatings, there is still room for improvement. This coating technique is still at its infancy 
and further optimization of the process parameters seems to be essential in order to produce 
nanocoatings capable of improving cell adhesion and exhibiting potent antibacterial activity 
even without the need of antibacterial agent. 
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4.2 Zusammenfassung und Ausblick 
Die Sprühtrocknung ist eine gut etablierte Methode, um flüssige Formulierungen in 
getrocknete Partikel umzuwandeln und sie weckt aufgrund ihrer zahlreichen Vorteile und 
breiten Einsatzmöglichkeiten weiterhin großes Interesse. Zudem konnten innerhalb des letzten 
Jahrzehnts durch die Einführung der Nanosprühtrocknung die Anwendungsmöglichkeiten des 
Verfahrens der Sprühtrocknung auf eine ganz neue Ebene gehoben werden, vor allem die 
Herstellung von Nanopartikeln ist hier zu erwähnen. 
Diese Doktorarbeit beinhaltet detaillierte Untersuchungen hinsichtlich der Anwendung der 
Sprühtrocknung in den beiden wichtigen Einsatzgebieten der pulmonalen 
Wirkstoffapplikation und der Beschichtung medizinischer Implantate. 
 
Die erste Zielsetzung war die Entwicklung einer Photosensitizer beladenen inhalativen 
Formulierung mittels Sprühtrocknung, die für die bronchoskopische photodynamische 
Therapie eingesetzt werden soll. Die pulmonale Applikation eines Photosensitizers stellt 
hierbei sowohl eine selektive als auch eine nicht-invasive Behandlungsmöglichkeit für 
Lungenkrebs dar, wodurch eine intravenöse Gabe vermieden und eine bessere Komplianz des 
Patienten erzielt werden können. 
Curcumin wurde als natürlich vorkommender Photosensitizer ausgewählt, obgleich dessen 
schlechte Wasserlöslichkeit und geringe Bioverfügbarkeit auf den ersten Blick große 
Nachteile darstellen. Aus diesem Grund erfolgte die Herstellung der Curcumin-Nanopartikel 
mithilfe der Nanopräzipitation, wodurch schlussendlich die Wirksamkeit des Photosensitizer 
gegenüber Tumorzellen erhöht werden konnte. Partikelgrößenmessungen, basierend auf dem 
Prinzip der dynamischen Lichtstreuung, zeigten eine für die zelluläre Aufnahme geeignete 
Partikelgröße mit homogener Größenverteilung. Darüber hinaus wiesen die Curcumin-
Nanopartikel eine gute Hämokompatibilität mit geringem hämolytischen Potential und 
keinem nennenswerten Einfluss auf die Koagulationszeit auf. In vitro 
Bestrahlungsexperimente mit humanen Lungenepithelkarzinomzellen (A549) zeigten eine 
effektive Photoaktivierung der Curcumin-Nanopartikel, da eine Abtötung der Karzinomzellen 
bei Bestrahlung mit Licht einer spezifischen Wellenlänge mithilfe einer LED-Apparatur 
gezeigt werden konnte. Zum einen ergab sich für Curcumin-Nanopartikel eine dosisabhängige 
Phototoxizität und zum anderen zeigten die IC50-Werte eine direkte Abhängigkeit von der 
aufgewendeten Fluenz. 
Die Herstellung der Nano-in-Mikropartikel erfolgte, indem die Curcumin-Nanopartikel mit 
dem Trägerstoff Mannitol versprüht wurden, wodurch die Nanopartikel in ein zur Inhalation 
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geeignetes, trockenes Pulver übergingen, ohne dabei drastischen Bedingungen ausgesetzt zu 
werden. Die aerodynamischen Eigenschaften der Nano-in-Mikropartikel wurden mithilfe des 
Next Generation Impactors analysiert und offenbarten eine große Feinpartikelfraktion mit 
einem für die pulmonale Applikation geeigneten, massenbezogenen medianen 
aerodynamischen Durchmesser. Die Nano-in-Mikropartikel wiesen eine gute 
Redispergierbarkeit und eine geeignete Desintegration in die ursprüngliche nanopartikuläre 
Struktur nach Überführung in wässrige Medien auf. Diese Eigenschaft kann primär dem 
Mannitol zugeschrieben werden, welches als Wandmaterial die Nanopartikel umschließt, um 
sie während des Trocknungsprozesses gegenüber unterschiedlichen Prozessparametern zu 
schützen und ihre Freisetzung aus den Mikropartikeln weiterhin zu gewährleisten. 
Experimente mithilfe des Monoschicht-Membranmodells (Wilhelmy-Filmwaage) bestätigten 
die Kompatibilität der Nano-in-Mikropartikel mit dem pulmonalen Surfactant, was eine 
Grundvoraussetzung für den sicheren Transport von Curcumin zum Wirkort in der Lunge ist 
(z.B. Tumorzellen). 
Diese Ergebnisse demonstrierten die Einsetzbarkeit der Sprühtrocknung zur der Herstellung 
inhalativer Arzneistoffträgersysteme mit erfolgversprechendem Potential im Bereich der 
photodynamischen Therapie. Als nächster Schritt sollten bei der Charakterisierung der 
Formulierungen bezüglich der Überwindung von biologischen Barrieren der Lunge in vivo 
Untersuchungen erfolgen. Darüber hinaus müsste eine Dosisanpassung für eine effektive 
Therapie durchgeführt werden. 
 
Die zweite Zielsetzung war die Einführung der Nanosprühtrocknung als neue Methode zur 
Herstellung von Nanopartikeln aus unterschiedlichen Biomaterialien, die gleichzeitig in der 
Lage ist, Oberflächenstrukturen von medizinischen Implantaten selbst mit schwieriger 
Topographie erfolgreich zu modifizieren. 
Der Nano-Sprühtrockner B-90, der sich durch eine fortschrittliche Funktionsweise und einen 
besonderen Aufbau auszeichnet, ermöglichte die Partikelproduktion und die Beschichtung 
von Implantaten in einem einzigen Schritt und machte zusätzliche Trocknungs- und 
Waschschritte überflüssig. Diese neue Beschichtungstechnik bietet viele Vorteile: 
a) Herstellung von Partikeln im Submikronbereich aus Lösungen von Reinsubstanzen ohne 
Zusatzstoffe (z.B. Surfactant) oder komplexe Modifikationen; b) sehr schonende 
Prozessbedingungen, die selbst für sensible und thermolabile Substanzen geeignet sind 
(z.B. Enzyme, Hormone und Nukleinsäuren); c) kostengünstiges und effizientes Verfahren, 
das nur eine geringe Probenmenge für ein gutes Resultat erfordert; d) einzigartiges 
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zylindrisches Design sowie außergewöhnliche Funktionsweise des Partikelkollektors 
ermöglichen ein erleichtertes Up-scaling des Verfahrens, da mehrere Implantate gleichzeitig 
auf dem Partikelkollektor aufgebracht werden können. 
In dieser Doktorarbeit ist die breite Anwendbarkeit dieser Technik anhand von drei 
repräsentativen Modellsubstanzen, Chitosan, Poly(lactid-co-glycolid) und Curcumin belegt. 
Vorläufige Versuche wurden auf Titanplättchen durchgeführt, um die Prozessparameter so 
anzupassen, dass eine kleine Partikelgröße mit enger Größenverteilung sowie eine komplette 
Bedeckung der Implantatoberfläche erreicht werden konnten. Nachfolgend wurden die 
optimierten Prozessparameter auf Zahnimplantate übertragen und erzielten eine homogene, 
durch Fluoreszenzmikroskopie nachgewiesene Beschichtung. Aufnahmen mithilfe des 
Rasterelektronenmikroskops zeigten, dass die meisten hergestellten Partikel im 
Submikronbereich lagen und eine sphärische Form mit glatter Oberfläche aufwiesen. Die 
Partikelgrößenanalyse offenbarte den Einfluss der Implantatposition innerhalb des 
Partikelkollektors auf die Partikelgrößenverteilung, wobei der untere Abschnitt des Kollektors 
die engste Partikelgrößenverteilung aufwies. 
Diese Ergebnisse stellten das Fundament für die Herstellung biokompatibler, antibakterieller 
Nanobeschichtungen dar. Die optimierten Prozessparameter aus den vorläufigen Versuchen 
fanden auf Titanplättchen Anwendung, die als Modellmaterial für Zahnimplantate dienten. 
Die hergestellten Nanobeschichtungen bestanden aus Poly(lactid-co-glycolid), einem 
bioabbaubaren Polymer, und Norfloxacin als Modellantibiotikum. Bildgebende 
Untersuchungen der Nanobeschichtungen mithilfe des Rasterelektronenmikroskops lieferten 
hinsichtlich der Partikelgrößenverteilung, Morphologie und Oberflächenstruktur Ergebnisse, 
wie sie bereits zuvor in den vorläufigen Versuchen festgestellt wurden, was die 
Reproduzierbarkeit der Beschichtungsmethode bestätigte. Die Nanobeschichtungen wiesen 
ein typisches zweiphasiges Freisetzungsprofil mit einer schnellen Freisetzung innerhalb der 
ersten 48 Stunden auf, der sich eine Freisetzung mit konstanter Geschwindigkeit bis zum 
Versuchsende anschloss. Die antibakterielle Wirkung der Nanobeschichtungen wurde gegen 
Escherichia coli in zwei Schritten evaluiert: Qualitativ durch den Agardiffusionstest, der es 
ermöglichte, eine große Probenanzahl zu analysieren, und quantitativ durch das Auszählen der 
Kolonie bildenden Einheiten, die auf der Oberfläche der Titanplättchen anhaften. Die 
antibakterielle Aktivität der mit Norfloxacin beladenen Nanobeschichtungen konnte als 
deutlich sichtbarer Hemmhof (Agardiffusionstest) sowie als signifikante Reduktion der 
Anzahl überlebender Bakterienkolonien identifiziert werden. Diese Aktivität war direkt vom 
Norfloxacin-Gehalt der Nanobeschichtung abhängig, der von der theoretischen Norfloxacin-
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Beladung und der Position der Titanplättchen im Partikelkollektor beeinflusst wurde. 
Abschließend erfolgte die Untersuchung der in vitro Biokompatibilität der 
Nanobeschichtungen an Mausfibroblasten (L929), die als Standard für sensitive Zelllinien bei 
zytotoxischen Analysen gelten. Die Zellproliferation auf der Oberfläche der Titanplättchen 
wurde mithilfe eines Fluoreszenzmikroskops visualisiert und anschließend durch die Analyse 
der Zellzahl quantifiziert. Beide Methoden bestätigten die Biokompatibilität der untersuchten 
Nanobeschichtungen, welche ähnliche Ergebnisse wie die unbeschichteten Titanplättchen 
aufzeigten. 
Obwohl die Nanosprühtrocknung ein solch vielversprechendes Potential bei der Herstellung 
neuer Nanobeschichtungen demonstrieren konnte, bleiben dennoch Verbesserungs-
möglichkeiten offen. Diese Beschichtungsmethode befindet sich noch immer in ihrer 
Anfangsphase und benötigt daher eine fortwährende Optimierung der Prozessparameter. So 
sollen zukünftig Nanobeschichtungen entwickelt werden, die sowohl die Adhäsion 
körpereigener Zellen verbessern als auch eine potente antibakterielle Aktivität aufweisen. Die 
zugrundeliegende Wirkung sollte dabei lediglich auf die Struktur ihrer Oberfläche 
zurückzuführen sein und so den Einsatz antibiotisch wirksamer Substanzen überflüssig 
machen. 
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